| AKT inhibitor VIII, Alternative-names: , CAS# 612847-09-3, Formula: C34H29N7O, MWT: 551.64036, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: Akt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more |
| MK 2206 (dihydrochloride), Alternative-names: , CAS# 1032350-13-2, Formula: C25H23Cl2N5O, MWT: 480.389, Solubility: DMSO: 4.8 mg/mL (Need ultrasonic and warming), Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;Autophagy, Target: Akt;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GSK-690693, Alternative-names: , CAS# 937174-76-0, Formula: C21H27N7O3, MWT: 425.4842, Solubility: DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;Autophagy, Target: Akt;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NVP-TAE 684, Alternative-names: , CAS# 761439-42-3, Formula: C30H40ClN7O3S, MWT: 614.2017, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| A-769662, Alternative-names: , CAS# 844499-71-4, Formula: C20H12N2O3S, MWT: 360.3859, Solubility: DMSO: 24 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;PI3K/Akt/mTOR, Target: AMPK;AMPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| CP-466722, Alternative-names: , CAS# 1080622-86-1, Formula: C17H15N7O2, MWT: 349.3467, Solubility: DMSO: 7 mg/mL (Need warming), Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;PI3K/Akt/mTOR, Target: ATM/ATR;ATM/ATR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| SR144528, Alternative-names: , CAS# 192703-06-3, Formula: C29H34ClN3O, MWT: 476.0528, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tozasertib, Alternative-names: MK-0457;VX 680, CAS# 639089-54-6, Formula: C23H28N8OS, MWT: 464.5864, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Epigenetics;Autophagy, Target: Aurora Kinase;Aurora Kinase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 250mg |
| Crolibulin, Alternative-names: EPC2407, CAS# 1000852-17-4, Formula: C18H17BrN4O3, MWT: 417.2566, Solubility: DMSO: 125 mg/mL, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Cytoskeleton, Target: Microtubule/Tubulin;Microtubule/Tubulin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| GSK-1070916, Alternative-names: GSK-1070916A, CAS# 942918-07-2, Formula: C30H33N7O, MWT: 507.6293, Solubility: DMSO: ≥ 26.5 mg/mL, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| ZM-447439, Alternative-names: , CAS# 331771-20-1, Formula: C29H31N5O4, MWT: 513.5875, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Nifenazone, Alternative-names: , CAS# 2139-47-1, Formula: C17H16N4O2, MWT: 308.3345, Solubility: DMSO: 32 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| MLN8054, Alternative-names: , CAS# 869363-13-3, Formula: C25H15ClF2N4O2, MWT: 476.862, Solubility: DMSO: ≥30 mg/mL (Need ultrasonic and warming), Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Aurora A inhibitor I, Alternative-names: , CAS# 1158838-45-9, Formula: C31H31ClFN7O2, MWT: 588.075, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GNF-2, Alternative-names: , CAS# 778270-11-4, Formula: C18H13F3N4O2, MWT: 374.3166, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Bcr-Abl, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Thymus factor X, Alternative-names: TFX-Jelfa, CAS# 78310-77-7, Formula: N/A, MWT: 1000, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| PRN694, Alternative-names: , CAS# 1575818-46-0, Formula: C28H35F2N5O2S, MWT: 543.6716, Solubility: DMSO: 125 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Itk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| IWP-4, Alternative-names: , CAS# 686772-17-8, Formula: C23H20N4O3S3, MWT: 496.6249, Solubility: DMSO: 5 mg/mL, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt, Target: Wnt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Navitoclax, Alternative-names: ABT-263, CAS# 923564-51-6, Formula: C47H55ClF3N5O6S3, MWT: 974.6127, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Apoptosis, Target: Bcl-2 Family, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Retinol, Alternative-names: Vitamin A1;all-trans-Retinol, CAS# 68-26-8, Formula: C20H30O, MWT: 286.4516, Solubility: DMSO, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| OICR-0547, Alternative-names: , CAS# 1801873-49-3, Formula: C28H29F3N4O4, MWT: 542.5495, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Diaveridine, Alternative-names: , CAS# 5355-16-8, Formula: C13H16N4O2, MWT: 260.2917, Solubility: DMSO: 32 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Anti-infection, Target: Antifolate;Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 250mg |
| ABT-737, Alternative-names: , CAS# 852808-04-9, Formula: C42H45ClN6O5S2, MWT: 813.4269, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Autophagy;Apoptosis, Target: Autophagy;Bcl-2 Family, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Bictegravir, Alternative-names: GS-9883, CAS# 1611493-60-7, Formula: C21H18F3N3O5, MWT: 449.3799, Solubility: DMSO: 83.3 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Integrase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Evocalcet, Alternative-names: KHK7580, CAS# 870964-67-3, Formula: C24H26N2O2, MWT: 374.4754, Solubility: DMSO: 30 mg/mL, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: CaSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| PCI-32765, Alternative-names: Ibrutinib, CAS# 936563-96-1, Formula: C25H24N6O2, MWT: 440.4971, Solubility: DMSO: ≥ 52 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK, Target: Btk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NVP-2, Alternative-names: , CAS# 1263373-43-8, Formula: C27H37ClN6O2, MWT: 513.07468, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| THZ531, Alternative-names: , CAS# 1702809-17-3, Formula: C30H32ClN7O2, MWT: 558.0738, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Esonarimod, Alternative-names: KE-298, CAS# 101973-77-7, Formula: C14H16O4S, MWT: 280.3394, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| BAY-598, Alternative-names: , CAS# 1906919-67-2, Formula: C22H20Cl2F2N6O3, MWT: 525.3354064, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Roscovitine, Alternative-names: CYC202; R-roscovitine; Seliciclib, CAS# 186692-46-6, Formula: C19H26N6O, MWT: 354.4493, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| AT7519, Alternative-names: , CAS# 844442-38-2, Formula: C16H17Cl2N5O2, MWT: 382.2445, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Flavopiridol, Alternative-names: L868275; HMR-1275; Alvocidib, CAS# 146426-40-6, Formula: C21H20ClNO5, MWT: 401.8402, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Autophagy, Target: CDK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Dolutegravir intermediate-1, Alternative-names: , CAS# 1335210-23-5, Formula: C13H17NO8, MWT: 315.276, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Delpazolid, Alternative-names: LCB01-0371, CAS# 1219707-39-7, Formula: C14H17FN4O3, MWT: 308.3082, Solubility: DMSO: 30 mg/mL, Clinical_Information: Phase 2, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Palbociclib, Alternative-names: PD 0332991, CAS# 571190-30-2, Formula: C24H29N7O2, MWT: 447.5327, Solubility: DMSO: 0.2 mg/mL (Need ultrasonic or warming), Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| NPS-1034, Alternative-names: , CAS# 1221713-92-3, Formula: C31H23F2N5O3, MWT: 551.5428, Solubility: DMSO: 34 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;TAM Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Ferrostatin-1, Alternative-names: , CAS# 347174-05-4, Formula: C15H22N2O2, MWT: 262.3474, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Ferroptosis , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BVT948, Alternative-names: , CAS# 39674-97-0, Formula: C14H11NO3, MWT: 241.242, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Metabolic Enzyme/Protease;Metabolic Enzyme/Protease, Target: Histone Methyltransferase;Cytochrome P450;Phosphatase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PHA-793887, Alternative-names: , CAS# 718630-59-2, Formula: C19H31N5O2, MWT: 361.4818, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Maltose monohydrate, Alternative-names: , CAS# 6363-53-7, Formula: C12H24O12, MWT: 360.31176, Solubility: H<sub>2</sub>O: 100 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Quadrol, Alternative-names: N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine;EDTP, CAS# 102-60-3, Formula: C14H32N2O4, MWT: 292.4149, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| HA-100, Alternative-names: , CAS# 84468-24-6, Formula: C13H15N3O2S, MWT: 277.3421, Solubility: DMSO: 150 mg/mL, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Protein Tyrosine Kinase/RTK;TGF-beta/Smad;Epigenetics;Cytoskeleton, Target: PKA;PKA;PKC;PKC;Myosin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PX20606 trans racemate, Alternative-names: PX-102 trans racemate, CAS# 1268244-85-4, Formula: C29H22Cl3NO4, MWT: 554.84828, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: FXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| (-)-PX20606 trans isomer, Alternative-names: (-)-PX-102 trans isomer;(-)-PX-104, CAS# 1268244-88-7, Formula: C29H22Cl3NO4, MWT: 554.84828, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: FXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| SNS-032, Alternative-names: BMS-387032, CAS# 345627-80-7, Formula: C17H24N4O2S2, MWT: 380.528, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| SR9238, Alternative-names: , CAS# 1416153-62-2, Formula: C31H33NO7S2, MWT: 595.72622, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: LXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Docosahexaenoic Acid methyl ester, Alternative-names: all cis-DHA methyl ester;Methyl docosahexaenoate, CAS# 2566-90-7, Formula: C23H34O2, MWT: 342.51486, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BMS-986205, Alternative-names: , CAS# 1923833-60-6, Formula: C24H24ClFN2O, MWT: 410.9115632, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Indoleamine 2,3-Dioxygenase (IDO), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| dBET1, Alternative-names: , CAS# 1799711-21-9, Formula: C38H37ClN8O7S, MWT: 785.26778, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;PROTAC, Target: Epigenetic Reader Domain;PROTAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| R547, Alternative-names: , CAS# 741713-40-6, Formula: C18H21F2N5O4S, MWT: 441.4522, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| 42-(2-Tetrazolyl)rapamycin, Alternative-names: , CAS# 221877-56-1, Formula: C52H79N5O12, MWT: 966.20996, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| AZD4635, Alternative-names: HTL1071, CAS# 1321514-06-0, Formula: C15H11ClFN5, MWT: 315.7327432, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Adenosine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LY 344864 racemate, Alternative-names: , CAS# 186543-64-6, Formula: C21H22FN3O, MWT: 351.4172832, Solubility: 10 mM in DMSO (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AZD-5438, Alternative-names: , CAS# 602306-29-6, Formula: C18H21N5O2S, MWT: 371.4566, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| (+)-BAY-1251152, Alternative-names: , CAS# 1610358-56-9, Formula: C19H18F2N4O2S, MWT: 404.4336264, Solubility: DMSO: 113.3 mg/mL, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LY3200882, Alternative-names: , CAS# 1898283-02-7, Formula: C24H29N5O3, MWT: 435.51876, Solubility: DMSO: 130 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ML327, Alternative-names: , CAS# 1883510-31-3, Formula: C19H18N4O4, MWT: 366.37062, Solubility: DMSO: 32 mg/mL, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: c-Myc, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| TLR7-agonist-1, Alternative-names: , CAS# 1642857-69-9, Formula: C17H16N6O2, MWT: 336.34794, Solubility: DMSO: 160 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: Toll-like Receptor (TLR), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| FAA1 agonist-1, Alternative-names: , CAS# 2102196-57-4, Formula: C21H17ClO5S, MWT: 416.87468, Solubility: DMSO: 160 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: GPR40, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| CGP60474, Alternative-names: , CAS# 164658-13-3, Formula: C18H18ClN5O, MWT: 355.8214, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Epigenetics, Target: PKC;PKC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AZD-7762, Alternative-names: , CAS# 860352-01-8, Formula: C17H19FN4O2S, MWT: 362.4218, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage, Target: Checkpoint Kinase (Chk), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LY334370, Alternative-names: , CAS# 182563-08-2, Formula: C21H22FN3O, MWT: 351.4172832, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GYKI53655 hydrochloride, Alternative-names: , CAS# 143692-48-2, Formula: C19H21ClN4O3, MWT: 388.84804, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: iGluR;iGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BAY 73-6691, Alternative-names: (R)-BAY 73-6691, CAS# 794568-92-6, Formula: C15H12ClF3N4O, MWT: 356.7301896, Solubility: DMSO: 160 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Neu2000, Alternative-names: , CAS# 640290-67-1, Formula: C15H8F7NO3, MWT: 383.2177424, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling, Target: iGluR;iGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| LTI-291, Alternative-names: , CAS# 1919820-28-2, Formula: C20H30N4O2, MWT: 358.4778, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Imatinib (Mesylate), Alternative-names: CGP-57148B;STI-571, CAS# 220127-57-1, Formula: C30H35N7O4S, MWT: 589.7084, Solubility: DMSO: ≥ 49 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK, Target: Bcr-Abl;PDGFR;Autophagy;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| PHTPP, Alternative-names: , CAS# 805239-56-9, Formula: C20H11F6N3O, MWT: 423.3112592, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Estrogen Receptor/ERR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| JNJ0966, Alternative-names: , CAS# 315705-75-0, Formula: C16H16N4O2S2, MWT: 360.45384, Solubility: DMSO: 160 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: MMP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Motesanib, Alternative-names: AMG 706;, CAS# 453562-69-1, Formula: C22H23N5O, MWT: 373.4509, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Panadoxine P, Alternative-names: , CAS# 36944-85-1, Formula: C8H10NO5P, MWT: 231.142462, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| AM-0902, Alternative-names: , CAS# 1883711-97-4, Formula: C17H15ClN6O2, MWT: 370.793, Solubility: DMSO: 150 mg/mL, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: TRP Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MZ 1, Alternative-names: , CAS# 1797406-69-9, Formula: C49H60ClN9O8S2, MWT: 1002.6392, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;PROTAC, Target: Epigenetic Reader Domain;PROTAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Crizotinib, Alternative-names: PF-02341066, CAS# 877399-52-5, Formula: C21H22Cl2FN5O, MWT: 450.3367, Solubility: DMSO: 55 mg/mL (Need ultrasonic), Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;Autophagy;ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| GSK2033, Alternative-names: , CAS# 1221277-90-2, Formula: C29H28F3NO5S2, MWT: 591.6615296, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: LXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tivantinib, Alternative-names: ARQ 197, CAS# 905854-02-6, Formula: C23H19N3O2, MWT: 369.4159, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| T6P unnatural precursors (1-4), Alternative-names: , CAS# 1404341-64-5, Formula: C21H32NO18P, MWT: 617.448442, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| JNJ-38877605, Alternative-names: , CAS# 943540-75-8, Formula: C19H13F2N7, MWT: 377.3502, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| VU6005649, Alternative-names: , CAS# 2137047-43-7, Formula: C16H12F5N3O, MWT: 357.277996, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Leu-AMS, Alternative-names: , CAS# 288591-93-5, Formula: C16H25N7O7S, MWT: 459.4774, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Morphothiadin, Alternative-names: GLS4, CAS# 1092970-12-1, Formula: C21H22BrFN4O3S, MWT: 509.3917832, Solubility: DMSO: 60 mg/mL, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HBV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| 5α-Pregnane-3β,6α-diol-20-one, Alternative-names: , CAS# 21853-11-2, Formula: C21H34O3, MWT: 334.49286, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Alisporivir intermediate-1, Alternative-names: AVVLAALLVXX, CAS# 882506-05-0, Formula: C74H132N12O17, MWT: 1461.91008, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Cot inhibitor-1, Alternative-names: , CAS# 915365-57-0, Formula: C27H27Cl2FN8, MWT: 553.4613, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: TNF-alpha, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| (S)-Purvalanol B, Alternative-names: (S)-NG 95, CAS# , Formula: C20H25ClN6O3, MWT: 432.9039, Solubility: DMSO: 76.7 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Aminoacyl tRNA synthetase-IN-1, Alternative-names: , CAS# 219931-45-0, Formula: C16H25N7O7S, MWT: 459.4774, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| GlyRS-IN-1, Alternative-names: , CAS# 112921-11-6, Formula: C12H17N7O7S, MWT: 403.37108, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| TRPM2 agonist-1, Alternative-names: , CAS# 863238-55-5, Formula: C17H18N6O8S, MWT: 466.42522, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: TRP Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| CA-4948, Alternative-names: , CAS# 1801343-74-7, Formula: C21H19N7O3, MWT: 417.42066, Solubility: DMSO: 31 mg/mL, Clinical_Information: Phase 1, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BRL-50481, Alternative-names: , CAS# 433695-36-4, Formula: C9H12N2O4S, MWT: 244.26758, Solubility: DMSO: 300 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Sabinene, Alternative-names: , CAS# 3387-41-5, Formula: C10H16, MWT: 136.23404, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Cenicriviroc Mesylate, Alternative-names: TAK-652 Mesylate;TBR-652 Mesylate, CAS# 497223-28-6, Formula: C42H56N4O7S2, MWT: 793.04664, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Cot inhibitor-2, Alternative-names: , CAS# 915363-56-3, Formula: C26H25Cl2FN8, MWT: 539.4347, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: TNF-alpha, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LY2562175, Alternative-names: , CAS# 1103500-20-4, Formula: C28H27Cl2N3O4, MWT: 540.43768, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: FXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| iCRT3, Alternative-names: , CAS# 901751-47-1, Formula: C23H26N2O2S, MWT: 394.52974, Solubility: DMSO: 150 mg/mL, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt, Target: Wnt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ROC-325, Alternative-names: , CAS# 1859141-26-6, Formula: C28H27ClN4OS, MWT: 503.05818, Solubility: DMSO: 32 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Autophagy, Target: Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SAR405 R enantiomer, Alternative-names: , CAS# 1946010-79-2, Formula: C19H21ClF3N5O2, MWT: 443.8505496, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| CBL0137 hydrochloride, Alternative-names: Curaxin-137 hydrochloride;CBL-C137 hydrochloride, CAS# 1197397-89-9, Formula: C21H25ClN2O2, MWT: 372.8884, Solubility: DMSO: 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Apoptosis;NF-κB, Target: MDM-2/p53;NF-κB, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Ethylhexyl triazone, Alternative-names: Octyl triazone, CAS# 88122-99-0, Formula: C48H66N6O6, MWT: 823.07424, Solubility: DMSO: 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Diethylamino hydroxybenzoyl hexyl benzoate, Alternative-names: DHHB, CAS# 302776-68-7, Formula: C24H31NO4, MWT: 397.50724, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| KU-57788, Alternative-names: NU7441, CAS# 503468-95-9, Formula: C25H19NO3S, MWT: 413.4883, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage;Epigenetics;Cell Cycle/DNA Damage, Target: DNA-PK;DNA-PK;Epigenetic Reader Domain;CRISPR/Cas9, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Neratinib, Alternative-names: HKI-272, CAS# 698387-09-6, Formula: C30H29ClN6O3, MWT: 557.0427, Solubility: DMSO: 6.4 mg/mL (Need ultrasonic), Clinical_Information: Phase 3, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Lapatinib, Alternative-names: GW572016, CAS# 231277-92-2, Formula: C29H26ClFN4O4S, MWT: 581.0576, Solubility: DMSO: ≥ 39 mg/mL, Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy, Target: EGFR;EGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Pelitinib, Alternative-names: EKB-569;WAY-EKB 569, CAS# 257933-82-7, Formula: C24H23ClFN5O2, MWT: 467.9231, Solubility: DMSO: 16 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: Src;EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CUDC-101, Alternative-names: , CAS# 1012054-59-9, Formula: C24H26N4O4, MWT: 434.4876, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Epigenetics;Cell Cycle/DNA Damage, Target: EGFR;EGFR;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-562271, Alternative-names: , CAS# 717907-75-0, Formula: C21H20F3N7O3S, MWT: 507.4888, Solubility: DMSO: ≥ 48 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Pyk2;FAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CCG-63802, Alternative-names: , CAS# 620112-78-9, Formula: C26H18N4O2S, MWT: 450.5117, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: RGS Protein, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CCG-63808, Alternative-names: , CAS# 620113-73-7, Formula: C25H15FN4O2S, MWT: 454.4756, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: RGS Protein, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Afatinib, Alternative-names: BIBW 2992, CAS# 850140-72-6, Formula: C24H25ClFN5O3, MWT: 485.9384032, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy, Target: EGFR;EGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| GSK1904529A, Alternative-names: , CAS# 1089283-49-7, Formula: C44H47F2N9O5S, MWT: 851.9631, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: IGF-1R, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TPCA-1, Alternative-names: , CAS# 507475-17-4, Formula: C12H10FN3O2S, MWT: 279.2901, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BMS-345541, Alternative-names: BMS-345541 hydrochloride, CAS# 547757-23-3, Formula: C14H18ClN5, MWT: 291.7792, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| IKK-3 Inhibitor, Alternative-names: , CAS# 862812-98-4, Formula: C22H19N3O5S2, MWT: 469.5334, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ITK inhibitor, Alternative-names: , CAS# 439574-61-5, Formula: C31H39N5O4S2, MWT: 609.8025, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Itk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BMS-509744, Alternative-names: , CAS# 439575-02-7, Formula: C32H41N5O4S2, MWT: 623.829, Solubility: DMSO: 21.9 mg/mL; in vivo: suspended with formulation of H2O:ethanol:Tween 80=90:5:5., Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Itk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AZD-1480, Alternative-names: AZD1480;AZD 1480, CAS# 935666-88-9, Formula: C14H14ClFN8, MWT: 348.766, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: JAK;JAK;JAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| TG-101348, Alternative-names: Fedratinib;SAR 302503, CAS# 936091-26-8, Formula: C27H36N6O3S, MWT: 524.6782, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: Phase 2, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Epigenetics, Target: JAK;JAK;JAK;Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| CYT387, Alternative-names: momelotinib, CAS# 1056634-68-4, Formula: C23H22N6O2, MWT: 414.4598, Solubility: DMSO: ≥ 40 mg/mL, Clinical_Information: Phase 3, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Autophagy, Target: JAK;JAK;JAK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| WHI-P97, Alternative-names: , CAS# 211555-05-4, Formula: C16H13Br2N3O3, MWT: 455.1007, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: JAK;JAK;JAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| BRAF inhibitor, Alternative-names: , CAS# 918505-61-0, Formula: C22H18F2N4O3S, MWT: 456.4651, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GSK-923295, Alternative-names: , CAS# 1088965-37-0, Formula: C32H38ClN5O4, MWT: 592.1282, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Cytoskeleton;Cell Cycle/DNA Damage, Target: Kinesin;Kinesin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| A-770041, Alternative-names: , CAS# 869748-10-7, Formula: C34H39N9O3, MWT: 621.7319, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Src, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CI-1040, Alternative-names: PD 184352, CAS# 212631-79-3, Formula: C17H14ClF2IN2O2, MWT: 478.6595, Solubility: DMSO: ≥ 150 mg/mL, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Selumetinib, Alternative-names: AZD6244;ARRY-142886, CAS# 606143-52-6, Formula: C17H15BrClFN4O3, MWT: 457.6814, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: Launched, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Trametinib, Alternative-names: GSK1120212;JTP-74057, CAS# 871700-17-3, Formula: C26H23FIN5O4, MWT: 615.3948, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
Trametinib (DMSO solvate), Alternative-names: GSK-1120212 DMSO solvate;Trametinib;JTP-74057;GSK1120212, CAS# 1187431-43-1, Formula: C28H29FIN5O5S, MWT: 693.5283, Solubility: DMSO: ≥ 69 mg/mL (Need ultrasonic)
, Clinical_Information: Launched, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PD0325901, Alternative-names: PD325901, CAS# 391210-10-9, Formula: C16H14F3IN2O4, MWT: 482.1931, Solubility: DMSO: ≥ 56 mg/mL, Clinical_Information: Phase 2, Pathway: Autophagy;MAPK/ERK Pathway, Target: Autophagy;MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Rapamycin, Alternative-names: Sirolimus, CAS# 53123-88-9, Formula: C51H79NO13, MWT: 914.17186, Solubility: DMSO: ≥ 28 mg/mL, Clinical_Information: Launched, Pathway: PI3K/Akt/mTOR, Target: mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Everolimus, Alternative-names: RAD001;SDZ-RAD, CAS# 159351-69-6, Formula: C53H83NO14, MWT: 958.2244, Solubility: DMSO: ≥ 54 mg/mL, Clinical_Information: Launched, Pathway: PI3K/Akt/mTOR, Target: mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2g |
| KU-0063794, Alternative-names: , CAS# 938440-64-3, Formula: C25H31N5O4, MWT: 465.5447, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| WYE-125132, Alternative-names: , CAS# 1144068-46-1, Formula: C27H33N7O4, MWT: 519.5954, Solubility: DMSO: ≥ 62 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| AZD-8055, Alternative-names: , CAS# 1009298-09-2, Formula: C25H31N5O4, MWT: 465.5447, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MLN4924 (hydrochloride), Alternative-names: Pevonedistat hydrochloride, CAS# 1160295-21-5, Formula: C21H26ClN5O4S, MWT: 479.9803, Solubility: DMSO: ≥ 160 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: NEDD8-activating Enzyme, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GSK461364, Alternative-names: GSK461364A, CAS# 929095-18-1, Formula: C27H28F3N5O2S, MWT: 543.6038, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage, Target: Polo-like Kinase (PLK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| GW843682X, Alternative-names: GW843682, CAS# 660868-91-7, Formula: C22H18F3N3O4S, MWT: 477.4562, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Polo-like Kinase (PLK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BI 2536, Alternative-names: , CAS# 755038-02-9, Formula: C28H39N7O3, MWT: 521.6544, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Polo-like Kinase (PLK);Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SB 239063, Alternative-names: , CAS# 193551-21-2, Formula: C20H21FN4O2, MWT: 368.4048, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TAK-715, Alternative-names: , CAS# 303162-79-0, Formula: C24H21N3OS, MWT: 399.508, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| VX-702, Alternative-names: , CAS# 745833-23-2, Formula: C19H12F4N4O2, MWT: 404.3178, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Olaparib, Alternative-names: AZD2281;KU0059436, CAS# 763113-22-0, Formula: C24H23FN4O3, MWT: 434.4628, Solubility: DMSO: 29 mg/mL, Clinical_Information: Launched, Pathway: Epigenetics;Cell Cycle/DNA Damage;Autophagy, Target: PARP;PARP;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Veliparib, Alternative-names: ABT-888, CAS# 912444-00-9, Formula: C13H16N4O, MWT: 244.2923, Solubility: DMSO: ≥ 29 mg/mL, Clinical_Information: Phase 3, Pathway: Epigenetics;Cell Cycle/DNA Damage;Autophagy, Target: PARP;PARP;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Veliparib (dihydrochloride), Alternative-names: ABT-888 dihydrochloride, CAS# 912445-05-7, Formula: C13H18Cl2N4O, MWT: 317.21422, Solubility: DMSO: ≥ 3.2 mg/mL, Clinical_Information: Phase 3, Pathway: Epigenetics;Cell Cycle/DNA Damage;Autophagy, Target: PARP;PARP;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| D609, Alternative-names: , CAS# 83373-60-8, Formula: C11H15KOS2, MWT: 266.4645, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phospholipase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BX-912, Alternative-names: , CAS# 702674-56-4, Formula: C20H23BrN8O, MWT: 471.3536, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PDK-1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| BEZ235, Alternative-names: NVP-BEZ235, CAS# 915019-65-7, Formula: C30H23N5O, MWT: 469.5365, Solubility: DMSO: 8.75 mg/mL, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| GDC-0941, Alternative-names: Pictilisib, CAS# 957054-30-7, Formula: C23H27N7O3S2, MWT: 513.6356, Solubility: DMSO: ≥ 29 mg/mL, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| GDC-0941 (dimethanesulfonate), Alternative-names: Pictilisib dimethanesulfonate;GDC-0941 (2 MeSO3H salt);GDC-0941, CAS# 957054-33-0, Formula: C25H35N7O9S4, MWT: 705.8469, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| ZSTK474, Alternative-names: , CAS# 475110-96-4, Formula: C19H21F2N7O2, MWT: 417.4125, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| AS-605240, Alternative-names: , CAS# 648450-29-7, Formula: C12H7N3O2S, MWT: 257.2679, Solubility: DMSO: 5.8 mg/mL (Need warming), Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GSK2126458, Alternative-names: Omipalisib, CAS# 1086062-66-9, Formula: C25H17F2N5O3S, MWT: 505.496, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AZD 6482, Alternative-names: KIN 193, CAS# 1173900-33-8, Formula: C22H24N4O4, MWT: 408.4503, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PP121, Alternative-names: , CAS# 1092788-83-4, Formula: C17H17N7, MWT: 319.3638, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;PI3K/Akt/mTOR, Target: Src;VEGFR;PDGFR;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PI3K inhibitor X, Alternative-names: , CAS# 956958-53-5, Formula: C21H16N6O2S2, MWT: 448.5208, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NVP-BKM120, Alternative-names: Buparlisib;BKM120, CAS# 944396-07-0, Formula: C18H21F3N6O2, MWT: 410.3936, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Sotrastaurin, Alternative-names: AEB071, CAS# 425637-18-9, Formula: C25H22N6O2, MWT: 438.4812, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: TGF-beta/Smad;Epigenetics, Target: PKC;PKC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AZ 628, Alternative-names: , CAS# 878739-06-1, Formula: C27H25N5O2, MWT: 451.5197, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GW 5074, Alternative-names: , CAS# 220904-83-6, Formula: C15H8Br2INO2, MWT: 520.942, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SB-590885, Alternative-names: , CAS# 405554-55-4, Formula: C27H27N5O2, MWT: 453.5356, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PLX-4720, Alternative-names: , CAS# 918505-84-7, Formula: C17H14ClF2N3O3S, MWT: 413.8262, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| GSK429286A, Alternative-names: , CAS# 864082-47-3, Formula: C21H16F4N4O2, MWT: 432.3709, Solubility: DMSO: ≥ 51 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Y-33075, Alternative-names: Y 39983, CAS# 199433-58-4, Formula: C16H16N4O, MWT: 280.3244, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
Nucleozin, Alternative-names: , CAS# 341001-38-5, Formula: C21H19ClN4O4, MWT: 426.853, Solubility: DMSO: 28.66 mg/mL (Need ultrasonic)
, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Dasatinib, Alternative-names: BMS-354825, CAS# 302962-49-8, Formula: C22H26ClN7O2S, MWT: 488.0056, Solubility: DMSO: 35.35 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy, Target: Src;Bcr-Abl;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Saracatinib, Alternative-names: AZD0530, CAS# 379231-04-6, Formula: C27H32ClN5O5, MWT: 542.0265, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: Src;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Nilotinib, Alternative-names: Tasigna;AMN107, CAS# 641571-10-0, Formula: C28H22F3N7O, MWT: 529.5158, Solubility: DMSO: 28 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: Bcr-Abl;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Tivozanib, Alternative-names: AV-951;KRN951, CAS# 475108-18-0, Formula: C22H19ClN4O5, MWT: 454.8631, Solubility: DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BIBF 1120, Alternative-names: Nintedanib, CAS# 656247-17-5, Formula: C31H33N5O4, MWT: 539.6248, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| MK-1775, Alternative-names: AZD1775;Adavosertib, CAS# 955365-80-7, Formula: C27H32N8O2, MWT: 500.5954, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage, Target: Wee1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Alisertib, Alternative-names: MLN 8237, CAS# 1028486-01-2, Formula: C27H20ClFN4O4, MWT: 518.9235, Solubility: DMSO: 9.33 mg/mL, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage;Epigenetics;Autophagy, Target: Aurora Kinase;Aurora Kinase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AT9283, Alternative-names: , CAS# 896466-04-9, Formula: C19H23N7O2, MWT: 381.4316, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Cell Cycle/DNA Damage;Epigenetics;Autophagy, Target: JAK;JAK;JAK;Aurora Kinase;Aurora Kinase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| AG-490, Alternative-names: Tyrphostin AG 490, CAS# 133550-30-8, Formula: C17H14N2O3, MWT: 294.3047, Solubility: DMSO: ≥57mg/mL , Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy;JAK/STAT Signaling;Stem Cell/Wnt, Target: EGFR;EGFR;Autophagy;STAT;STAT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Lenvatinib, Alternative-names: E7080, CAS# 417716-92-8, Formula: C21H19ClN4O4, MWT: 426.853, Solubility: DMSO, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TGX-221, Alternative-names: , CAS# 663619-89-4, Formula: C21H24N4O2, MWT: 364.4409, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| WZ-3146, Alternative-names: , CAS# 1214265-56-1, Formula: C24H25ClN6O2, MWT: 464.9473, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CYC-116, Alternative-names: , CAS# 693228-63-6, Formula: C18H20N6OS, MWT: 368.456, Solubility: DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SNS-314, Alternative-names: SNS-314 Mesylate, CAS# 1146618-41-8, Formula: C19H19ClN6O4S3, MWT: 527.04, Solubility: DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Fingolimod (hydrochloride), Alternative-names: FTY720, CAS# 162359-56-0, Formula: C19H34ClNO2, MWT: 343.9318, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation, Target: SPHK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
Linifanib, Alternative-names: ABT-869;AL-39324, CAS# 796967-16-3, Formula: C21H18FN5O, MWT: 375.3989, Solubility:
DMSO ≥72mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;FLT3;PDGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BMS-536924, Alternative-names: , CAS# 468740-43-4, Formula: C25H26ClN5O3, MWT: 479.9586, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: IGF-1R;Insulin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Cediranib, Alternative-names: AZD2171, CAS# 288383-20-0, Formula: C25H27FN4O3, MWT: 450.5053, Solubility: DMSO: ≥ 49 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;PDGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Dovitinib, Alternative-names: CHIR-258;TKI258;TKI-258;TKI 258;CHIR258;CHIR 258, CAS# 405169-16-6, Formula: C21H21FN6O, MWT: 392.4294, Solubility: DMSO: 25 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;FLT3;PDGFR;FGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Deforolimus, Alternative-names: AP23573;MK-8669;Ridaforolimus, CAS# 572924-54-0, Formula: C53H84NO14P, MWT: 990.2061, Solubility: DMSO: ≥ 44 mg/mL, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Erlotinib (Hydrochloride), Alternative-names: CP-358774;OSI-774;NSC 718781, CAS# 183319-69-9, Formula: C22H24ClN3O4, MWT: 429.8967, Solubility: DMSO: ≥ 4.3 mg/mL; DMSO: 6.2 mg/mL (Need ultrasonic and warming), Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy, Target: EGFR;EGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10g |
| Gefitinib, Alternative-names: ZD1839, CAS# 184475-35-2, Formula: C22H24ClFN4O3, MWT: 446.9024, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy, Target: EGFR;EGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| Lenalidomide, Alternative-names: CC-5013, CAS# 191732-72-6, Formula: C13H13N3O3, MWT: 259.2606, Solubility: DMSO: ≥ 35 mg/mL, Clinical_Information: Launched, Pathway: Apoptosis, Target: TNF-alpha, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Pazopanib (Hydrochloride), Alternative-names: GW786034, CAS# 635702-64-6, Formula: C21H24ClN7O2S, MWT: 473.979, Solubility: DMSO: 6.4 mg/mL (Need warming), Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;Autophagy;c-Fms;FGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| PI-103, Alternative-names: , CAS# 371935-74-9, Formula: C19H16N4O3, MWT: 348.3553, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Tandutinib, Alternative-names: MLN518;CT53518, CAS# 387867-13-2, Formula: C31H42N6O4, MWT: 562.703, Solubility: DMSO: ≥ 36 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK, Target: FLT3, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Vandetanib, Alternative-names: ZD6474, CAS# 443913-73-3, Formula: C22H24BrFN4O2, MWT: 475.354, Solubility: DMSO: 27.5 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Y-27632, Alternative-names: , CAS# 146986-50-7, Formula: C14H21N3O, MWT: 247.336, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Enzastaurin, Alternative-names: LY317615, CAS# 170364-57-5, Formula: C32H29N5O2, MWT: 515.605, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: TGF-beta/Smad;Epigenetics;Autophagy, Target: PKC;PKC;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Obatoclax, Alternative-names: Obatoclax Mesylate;GX15-070, CAS# 803712-79-0, Formula: C21H23N3O4S, MWT: 413.49, Solubility: DMSO: ≥ 48.8 mg/mL, Clinical_Information: Phase 3, Pathway: Autophagy;Apoptosis, Target: Autophagy;Bcl-2 Family, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Masitinib, Alternative-names: AB1010, CAS# 790299-79-5, Formula: C28H30N6OS, MWT: 498.6424, Solubility: DMSO: ≥ 26 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: PDGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
SB-431542, Alternative-names: , CAS# 301836-41-9, Formula: C22H16N4O3, MWT: 384.3875, Solubility: DMSO: ≥ 40 mg/mL; Ethanol: 11.17 mg/mL (Need ultrasonic and warming)
, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NVP-AUY922, Alternative-names: Luminespib;AUY922;VER-52296, CAS# 747412-49-3, Formula: C26H31N3O5, MWT: 465.5414, Solubility: DMSO: ≥ 62 mg/mL, Clinical_Information: Phase 2, Pathway: Autophagy;Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: Autophagy;HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PHA-665752, Alternative-names: , CAS# 477575-56-7, Formula: C32H34Cl2N4O4S, MWT: 641.6078, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: c-Met/HGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| HA14-1, Alternative-names: , CAS# 65673-63-4, Formula: C17H17BrN2O5, MWT: 409.2313, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Bcl-2 Family, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SB 216763, Alternative-names: , CAS# 280744-09-4, Formula: C19H12Cl2N2O2, MWT: 371.2168, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;PI3K/Akt/mTOR;Autophagy, Target: GSK-3;GSK-3;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| SB 203580, Alternative-names: RWJ 64809, CAS# 152121-47-6, Formula: C21H16FN3OS, MWT: 377.4346, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway;PI3K/Akt/mTOR;Autophagy, Target: p38 MAPK;Akt;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| SB 202190, Alternative-names: , CAS# 152121-30-7, Formula: C20H14FN3O, MWT: 331.343, Solubility: DMSO: ≥ 40 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway;Autophagy, Target: p38 MAPK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| PD153035 (Hydrochloride), Alternative-names: ZM 252868;AG 1517;Tyrphostin AG 1517;SU 5271;PD 153035, CAS# 183322-45-4, Formula: C16H15BrClN3O2, MWT: 396.6662, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PD153035, Alternative-names: ZM 252868;Tyrphostin AG 1517;AG 1517;SU 5271, CAS# 153436-54-5, Formula: C16H14BrN3O2, MWT: 360.2053, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SU11274, Alternative-names: PKI-SU11274, CAS# 658084-23-2, Formula: C28H30ClN5O4S, MWT: 568.0869, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: c-Met/HGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BSI-201, Alternative-names: Iniparib;NSC-746045;IND-71677, CAS# 160003-66-7, Formula: C7H5IN2O3, MWT: 292.0307, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: PARP;PARP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| KU-55933, Alternative-names: , CAS# 587871-26-9, Formula: C21H17NO3S2, MWT: 395.4946, Solubility: DMSO: 80 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Autophagy;Cell Cycle/DNA Damage;PI3K/Akt/mTOR, Target: Autophagy;ATM/ATR;ATM/ATR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PF-04217903, Alternative-names: , CAS# 956905-27-4, Formula: C19H16N8O, MWT: 372.3833, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Brivanib, Alternative-names: BMS-540215, CAS# 649735-46-6, Formula: C19H19FN4O3, MWT: 370.3776, Solubility: DMSO: ≥ 50 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Vatalanib (dihydrochloride), Alternative-names: PTK787 dihydrochloride;PTK/ZK dihydrochloride;CGP-79787D dihydrochloride;CGP-79787 dihydrochloride;ZK-222584 dihydrochloride, CAS# 212141-51-0, Formula: C20H17Cl3N4, MWT: 419.7348, Solubility: DMSO: ≥25mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| LY294002, Alternative-names: NSC 697286;SF 1101, CAS# 154447-36-6, Formula: C19H17NO3, MWT: 307.3432, Solubility: DMSO: 14.9 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Danusertib, Alternative-names: PHA-739358, CAS# 827318-97-8, Formula: C26H30N6O3, MWT: 474.5548, Solubility: DMSO: 7.5 mg/mL, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Epigenetics;Autophagy, Target: Aurora Kinase;Aurora Kinase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Foretinib, Alternative-names: XL880;GSK1363089;GSK089;EXEL-2880, CAS# 849217-64-7, Formula: C34H34F2N4O6, MWT: 632.6537, Solubility: DMSO: ≥ 38 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SGX-523, Alternative-names: , CAS# 1022150-57-7, Formula: C18H13N7S, MWT: 359.4077, Solubility: DMSO: ≥ 3.6 mg/mL, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| TW-37, Alternative-names: , CAS# 877877-35-5, Formula: C33H35NO6S, MWT: 573.6991, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Bcl-2 Family, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Abiraterone, Alternative-names: CB-7598, CAS# 154229-19-3, Formula: C24H31NO, MWT: 349.509, Solubility: DMSO: < 1 mg/mL; H<sub>2</sub>O: < 1 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Cytochrome P450, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| INO-1001, Alternative-names: 3-Aminobenzamide, CAS# 3544-24-9, Formula: C7H8N2O, MWT: 136.1512, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: PARP;PARP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| GDC-0879, Alternative-names: , CAS# 905281-76-7, Formula: C19H18N4O2, MWT: 334.3718, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Brivanib (alaninate), Alternative-names: BMS-582664, CAS# 649735-63-7, Formula: C22H24FN5O4, MWT: 441.4555, Solubility: DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Andarine, Alternative-names: GTx-007;S-4, CAS# 401900-40-1, Formula: C19H18F3N3O6, MWT: 441.3579, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Androgen Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| 17-AAG, Alternative-names: Tanespimycin;NSC 330507;CP 127374, CAS# 75747-14-7, Formula: C31H43N3O8, MWT: 585.6884, Solubility: DMSO: ≥ 55 mg/mL, Clinical_Information: Phase 3, Pathway: Autophagy;Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: Autophagy;HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Alvespimycin (hydrochloride), Alternative-names: 17-DMAG;KOS-1022;NSC 707545, CAS# 467214-21-7, Formula: C32H49ClN4O8, MWT: 653.2065, Solubility: DMSO: ≥ 50 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| AZD1152-HQPA, Alternative-names: Barasertib-HQPA;INH-34, CAS# 722544-51-6, Formula: C26H30FN7O3, MWT: 507.5599, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Sorafenib (Tosylate), Alternative-names: Bay 43-9006, CAS# 475207-59-1, Formula: C28H24ClF3N4O6S, MWT: 637.0266, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK, Target: VEGFR;Raf;FLT3;PDGFR;Autophagy;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10g |
| Pomalidomide, Alternative-names: CC-4047, CAS# 19171-19-8, Formula: C13H11N3O4, MWT: 273.2441, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Apoptosis, Target: TNF-alpha, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Serdemetan, Alternative-names: JNJ-26854165, CAS# 881202-45-5, Formula: C21H20N4, MWT: 328.4103, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Apoptosis, Target: MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| WZ4002, Alternative-names: , CAS# 1213269-23-8, Formula: C25H27ClN6O3, MWT: 494.9733, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BIIB021, Alternative-names: CNF2024, CAS# 848695-25-0, Formula: C14H15ClN6O, MWT: 318.7615, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: Phase 2, Pathway: Autophagy;Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: Autophagy;HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| PD98059, Alternative-names: , CAS# 167869-21-8, Formula: C16H13NO3, MWT: 267.2793, Solubility: DMSO: 16 mg/mL; H<sub>2</sub>O: < 0.01 mg/mL, Clinical_Information: No Development Reported, Pathway: Autophagy;MAPK/ERK Pathway, Target: Autophagy;MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Regorafenib, Alternative-names: BAY 73-4506, CAS# 755037-03-7, Formula: C21H15ClF4N4O3, MWT: 482.8154, Solubility: DMSO: ≥ 260 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;Raf;PDGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| WZ8040, Alternative-names: , CAS# 1214265-57-2, Formula: C24H25ClN6OS, MWT: 481.0129, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PIK-90, Alternative-names: , CAS# 677338-12-4, Formula: C18H17N5O3, MWT: 351.3593, Solubility: DMSO: < 1 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| U0126, Alternative-names: U0126-EtOH, CAS# 1173097-76-1, Formula: C20H22N6OS2, MWT: 426.55828, Solubility: DMSO: ≥ 49 mg/mL, Clinical_Information: No Development Reported, Pathway: Autophagy;MAPK/ERK Pathway, Target: Autophagy;MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| OSI-930, Alternative-names: , CAS# 728033-96-3, Formula: C22H16F3N3O2S, MWT: 443.4416, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;c-Fms;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AG14361, Alternative-names: , CAS# 328543-09-5, Formula: C19H20N4O, MWT: 320.3883, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: PARP;PARP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| 2-Methoxyestradiol, Alternative-names: 2-ME2;NSC-659853, CAS# 362-07-2, Formula: C19H26O3, MWT: 302.4079, Solubility: DMSO: ≥ 36 mg/mL; H<sub>2</sub>O: < 0.1 mg/mL, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Cytoskeleton;Autophagy;Metabolic Enzyme/Protease, Target: Microtubule/Tubulin;Microtubule/Tubulin;Autophagy;HIF/HIF Prolyl-Hydroxylase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Amuvatinib, Alternative-names: MP470;HPK 56, CAS# 850879-09-3, Formula: C23H21N5O3S, MWT: 447.5096, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: FLT3;PDGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| JNJ-7706621, Alternative-names: , CAS# 443797-96-4, Formula: C15H12F2N6O3S, MWT: 394.356, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Cell Cycle/DNA Damage;Epigenetics, Target: CDK;Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BMS-708163, Alternative-names: Avagacestat, CAS# 1146699-66-2, Formula: C20H17ClF4N4O4S, MWT: 520.885, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Stem Cell/Wnt;Neuronal Signaling;Stem Cell/Wnt, Target: γ-secretase;γ-secretase;Notch, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CHIR-99021, Alternative-names: CT99021, CAS# 252917-06-9, Formula: C22H18Cl2N8, MWT: 465.3379, Solubility: DMSO: ≥ 5.1 mg/mL, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;PI3K/Akt/mTOR;Autophagy, Target: GSK-3;GSK-3;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| PD173074, Alternative-names: , CAS# 219580-11-7, Formula: C28H41N7O3, MWT: 523.6702, Solubility: DMSO: ≥ 52 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
WYE-354, Alternative-names: , CAS# 1062169-56-5, Formula: C24H29N7O5, MWT: 495.5309, Solubility: DMSO: ≥ 26 mg/mL
, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| IC-87114, Alternative-names: , CAS# 371242-69-2, Formula: C22H19N7O, MWT: 397.4326, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AMG-208, Alternative-names: , CAS# 1002304-34-8, Formula: C22H17N5O2, MWT: 383.4027, Solubility: DMSO: < 1 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| TG100-115, Alternative-names: , CAS# 677297-51-7, Formula: C18H14N6O2, MWT: 346.3428, Solubility: DMSO: 5.45 mg/mL (Need ultrasonic and warming) , Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GSK1059615, Alternative-names: , CAS# 958852-01-2, Formula: C18H11N3O2S, MWT: 333.3638, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| MGCD-265 analog, Alternative-names: , CAS# 875337-44-3, Formula: C26H20FN5O2S2, MWT: 517.5977, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Rigosertib (sodium), Alternative-names: ON-01910 sodium, CAS# 592542-60-4, Formula: C21H24NNaO8S, MWT: 473.4719, Solubility: H<sub>2</sub>O: ≥ 52 mg/mL, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage, Target: Polo-like Kinase (PLK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Ki8751, Alternative-names: , CAS# 228559-41-9, Formula: C24H18F3N3O4, MWT: 469.4126, Solubility: DMSO: ≥92mg/mL; Water: <1.2mg/mL; Ethanol: <1.2mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Lyn-IN-1, Alternative-names: , CAS# 887650-05-7, Formula: C30H31F3N8O, MWT: 576.6154, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Bcr-Abl, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Elesclomol, Alternative-names: STA-4783, CAS# 488832-69-5, Formula: C19H20N4O2S2, MWT: 400.5177, Solubility: DMSO: ≥ 22 mg/mL, Clinical_Information: Phase 3, Pathway: Apoptosis, Target: Apoptosis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Motesanib (Diphosphate), Alternative-names: Motesanib;AMG 706, CAS# 857876-30-3, Formula: C22H29N5O9P2, MWT: 569.4413, Solubility: DMSO: ≥110mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| PHA-680632, Alternative-names: , CAS# 398493-79-3, Formula: C28H35N7O2, MWT: 501.6232, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
VX-745, Alternative-names: Neflamapimod, CAS# 209410-46-8, Formula: C19H9Cl2F2N3OS, MWT: 436.2621, Solubility: DMSO: 13.08 mg/mL (Need ultrasonic)
, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SP600125, Alternative-names: , CAS# 129-56-6, Formula: C14H8N2O, MWT: 220.2261, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway;Autophagy, Target: JNK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| TSU-68, Alternative-names: SU6668, CAS# 252916-29-3, Formula: C18H18N2O3, MWT: 310.3471, Solubility: DMSO: ≥ 28 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AS703026, Alternative-names: Pimasertib;MSC1936369B, CAS# 1236699-92-5, Formula: C15H15FIN3O3, MWT: 431.2008, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| SB 525334, Alternative-names: , CAS# 356559-20-1, Formula: C21H21N5, MWT: 343.4249, Solubility: DMSO: ≥ 46 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SU 5402, Alternative-names: , CAS# 215543-92-3, Formula: C17H16N2O3, MWT: 296.3205, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Cabozantinib (S-malate), Alternative-names: XL184;Cabozantinib, CAS# 1140909-48-3, Formula: C32H30FN3O10, MWT: 635.5931, Solubility: DMSO: ≥ 23 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| HMN-214, Alternative-names: IVX-214, CAS# 173529-46-9, Formula: C22H20N2O5S, MWT: 424.4696, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Polo-like Kinase (PLK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PIK-93, Alternative-names: , CAS# 593960-11-3, Formula: C14H16ClN3O4S2, MWT: 389.8775, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;PI4K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ponatinib, Alternative-names: AP24534, CAS# 943319-70-8, Formula: C29H27F3N6O, MWT: 532.5595, Solubility: DMSO: ≥ 50 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;Bcr-Abl;PDGFR;Autophagy;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Chelerythrine Chloride, Alternative-names: , CAS# 3895-92-9, Formula: C21H18ClNO4, MWT: 383.8249, Solubility: DMSO: ≥ 3.9 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway;TGF-beta/Smad;Epigenetics;Autophagy, Target: p38 MAPK;PKC;PKC;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| CCT129202, Alternative-names: , CAS# 942947-93-5, Formula: C23H25ClN8OS, MWT: 497.0156, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CP-673451, Alternative-names: , CAS# 343787-29-1, Formula: C24H27N5O2, MWT: 417.5035, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: PDGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LY2228820, Alternative-names: Ralimetinib dimesylate;LY2228820 dimesylate;LY2228820 2MsOH;, CAS# 862507-23-1, Formula: C26H37FN6O6S2, MWT: 612.737, Solubility: DMSO: < 7.8 mg/mL, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
Perifosine, Alternative-names: KRX-0401;NSC 639966;D21266, CAS# 157716-52-4, Formula: C25H52NO4P, MWT: 461.6584, Solubility:
DMSO <0.1 mg/mL; Water: ≥153 mg/mL, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR;Autophagy, Target: Akt;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| ENMD-2076 (Tartrate), Alternative-names: , CAS# 1291074-87-7, Formula: C25H31N7O6, MWT: 525.5569, Solubility: DMSO: ≥31 mg/mL , Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;FLT3;PDGFR;Aurora Kinase;Aurora Kinase;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Quizartinib, Alternative-names: AC220, CAS# 950769-58-1, Formula: C29H32N6O4S, MWT: 560.6672, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: FLT3;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Vinorelbine, Alternative-names: KW-2307 base, CAS# 71486-22-1, Formula: C45H54N4O8, MWT: 778.93226, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Cytoskeleton;Autophagy, Target: Microtubule/Tubulin;Microtubule/Tubulin;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Hesperadin, Alternative-names: , CAS# 422513-13-1, Formula: C29H32N4O3S, MWT: 516.6544, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics;Autophagy, Target: Aurora Kinase;Aurora Kinase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BIX02188, Alternative-names: , CAS# 334949-59-6, Formula: C25H24N4O2, MWT: 412.4837, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BIX02189, Alternative-names: , CAS# 1265916-41-3, Formula: C27H28N4O2, MWT: 440.5368, Solubility: DMSO: ≥ 49.4 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Vemurafenib, Alternative-names: RG7204;R7204;RO5185426;PLX4032, CAS# 918504-65-1, Formula: C23H18ClF2N3O3S, MWT: 489.9221, Solubility: DMSO: 6.2 mg/mL, Clinical_Information: Launched, Pathway: MAPK/ERK Pathway;Autophagy, Target: Raf;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| AZD8330, Alternative-names: ARRY-424704;ARRY-704;AZD8330, CAS# 869357-68-6, Formula: C16H17FIN3O4, MWT: 461.2267, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AT7867, Alternative-names: , CAS# 857531-00-1, Formula: C20H20ClN3, MWT: 337.8459, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Protein Tyrosine Kinase/RTK;PI3K/Akt/mTOR;MAPK/ERK Pathway, Target: PKA;PKA;Akt;Ribosomal S6 Kinase (RSK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Doramapimod, Alternative-names: BIRB 796, CAS# 285983-48-4, Formula: C31H37N5O3, MWT: 527.6572, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: MAPK/ERK Pathway;MAPK/ERK Pathway, Target: p38 MAPK;Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| KRN-633, Alternative-names: , CAS# 286370-15-8, Formula: C20H21ClN4O4, MWT: 416.8582, Solubility: DMSO: ≥8mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| KU-60019, Alternative-names: , CAS# 925701-46-8, Formula: C30H33N3O5S, MWT: 547.6651, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;PI3K/Akt/mTOR, Target: ATM/ATR;ATM/ATR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PD318088, Alternative-names: , CAS# 391210-00-7, Formula: C16H13BrF3IN2O4, MWT: 561.0891, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PHT-427, Alternative-names: , CAS# 1191951-57-1, Formula: C20H31N3O2S2, MWT: 409.609, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: Akt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TWS119, Alternative-names: , CAS# 601514-19-6, Formula: C18H14N4O2, MWT: 318.3293, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;PI3K/Akt/mTOR;Autophagy, Target: GSK-3;GSK-3;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Fasudil (Hydrochloride), Alternative-names: HA-1077;AT-877;Fasudil HCl, CAS# 105628-07-7, Formula: C14H18ClN3O2S, MWT: 327.8296, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: Launched, Pathway: TGF-beta/Smad;Epigenetics;TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage;Autophagy, Target: PKC;PKC;ROCK;ROCK;ROCK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| NVP-BEP800, Alternative-names: VER-82576, CAS# 847559-80-2, Formula: C21H23Cl2N5O2S, MWT: 480.4106, Solubility: DMSO: 6.2 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| BMS 777607, Alternative-names: BMS 817378, CAS# 1025720-94-8, Formula: C25H19ClF2N4O4, MWT: 512.8926, Solubility: DMSO: ≥ 39 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;TAM Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GSK1292263, Alternative-names: , CAS# 1032823-75-8, Formula: C23H28N4O4S, MWT: 456.5578, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: Phase 2, Pathway: GPCR/G Protein, Target: GPR119, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| R406, Alternative-names: , CAS# 841290-81-1, Formula: C28H29FN6O8S, MWT: 628.6287, Solubility: DMSO: ≥ 61 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Syk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PI3K-IN-1, Alternative-names: , CAS# 1349796-36-6, Formula: C31H29N5O6S, MWT: 599.6569, Solubility: DMSO: 27.5 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| KW-2449, Alternative-names: , CAS# 1000669-72-6, Formula: C20H20N4O, MWT: 332.399, Solubility: DMSO, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK, Target: Bcr-Abl;FLT3;Aurora Kinase;Aurora Kinase;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| RAF265, Alternative-names: CHIR-265, CAS# 927880-90-8, Formula: C24H16F6N6O, MWT: 518.4139, Solubility: DMSO: ≥ 26 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Autophagy, Target: VEGFR;Raf;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SB-743921, Alternative-names: , CAS# 940929-33-9, Formula: C31H34Cl2N2O3, MWT: 553.5193, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cytoskeleton;Cell Cycle/DNA Damage, Target: Kinesin;Kinesin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BAY 61-3606 (dihydrochloride), Alternative-names: BAY 61-3606, CAS# 648903-57-5, Formula: C20H20Cl2N6O3, MWT: 463.3172, Solubility: DMSO: ≥ 4.6 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Syk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BAY 61-3606, Alternative-names: , CAS# 732983-37-8, Formula: C20H18N6O3, MWT: 390.3953, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Syk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Torin 2, Alternative-names: , CAS# 1223001-51-1, Formula: C24H15F3N4O, MWT: 432.3973, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage;PI3K/Akt/mTOR;Autophagy, Target: DNA-PK;DNA-PK;mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Torin 1, Alternative-names: , CAS# 1222998-36-8, Formula: C35H28F3N5O2, MWT: 607.6243, Solubility: DMSO: 6.6 mg/mL (Need ultrasonic or warming), Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage;PI3K/Akt/mTOR;Autophagy, Target: DNA-PK;DNA-PK;mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| VE-821, Alternative-names: , CAS# 1232410-49-9, Formula: C18H16N4O3S, MWT: 368.4096, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;PI3K/Akt/mTOR, Target: ATM/ATR;ATM/ATR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CDK-IN-2, Alternative-names: CDK inhibitor II, CAS# 1269815-17-9, Formula: C18H19ClFN3O2, MWT: 363.8138, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SU14813, Alternative-names: , CAS# 627908-92-3, Formula: C23H27FN4O4, MWT: 442.4833, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Toceranib, Alternative-names: PHA 291639;SU11654, CAS# 356068-94-5, Formula: C22H25FN4O2, MWT: 396.4579, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Linsitinib, Alternative-names: OSI-906, CAS# 867160-71-2, Formula: C26H23N5O, MWT: 421.4937, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: IGF-1R;Insulin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TAK-901, Alternative-names: , CAS# 934541-31-8, Formula: C28H32N4O3S, MWT: 504.6437, Solubility: DMSO, Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BMS-690514, Alternative-names: , CAS# 859853-30-8, Formula: C19H24N6O2, MWT: 368.4329, Solubility: DMSO, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: VEGFR;EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| XMD8-92, Alternative-names: , CAS# 1234480-50-2, Formula: C26H30N6O3, MWT: 474.5548, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;MAPK/ERK Pathway, Target: ERK;ERK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LRRK2-IN-1, Alternative-names: , CAS# 1234480-84-2, Formula: C31H38N8O3, MWT: 570.6852, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Autophagy, Target: LRRK2, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PP 242, Alternative-names: , CAS# 1092351-67-1, Formula: C16H16N6O, MWT: 308.3378, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| KX2-391, Alternative-names: KX-01, CAS# 897016-82-9, Formula: C26H29N3O3, MWT: 431.5268, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Cytoskeleton, Target: Src;Microtubule/Tubulin;Microtubule/Tubulin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MRT67307, Alternative-names: , CAS# 1190378-57-4, Formula: C26H36N6O2, MWT: 464.603, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Autophagy;NF-κB, Target: Autophagy;IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| DPH, Alternative-names: , CAS# 484049-04-9, Formula: C18H13FN4O2, MWT: 336.3198, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Bcr-Abl, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CGI-1746, Alternative-names: , CAS# 910232-84-7, Formula: C34H37N5O4, MWT: 579.6887, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: Btk;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MK-0752, Alternative-names: , CAS# 471905-41-6, Formula: C21H21ClF2O4S, MWT: 442.9038464, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Stem Cell/Wnt;Neuronal Signaling, Target: γ-secretase;γ-secretase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GW788388, Alternative-names: , CAS# 452342-67-5, Formula: C25H23N5O2, MWT: 425.4824, Solubility: DMSO: ≥ 48 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Vismodegib, Alternative-names: GDC-0449, CAS# 879085-55-9, Formula: C19H14Cl2N2O3S, MWT: 421.2971, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Stem Cell/Wnt;Autophagy, Target: Hedgehog;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| CAL-101, Alternative-names: GS-1101;Idelalisib, CAS# 870281-82-6, Formula: C22H18FN7O, MWT: 415.423, Solubility: DMSO: ≥ 59.7 mg/mL, Clinical_Information: Launched, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| OSI-027, Alternative-names: , CAS# 936890-98-1, Formula: C21H22N6O3, MWT: 406.4378, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Palomid 529, Alternative-names: P529, CAS# 914913-88-5, Formula: C24H22O6, MWT: 406.4279, Solubility: DMSO: 20.5 mg/mL, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR, Target: mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BX795, Alternative-names: , CAS# 702675-74-9, Formula: C23H26IN7O2S, MWT: 591.4677, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PDK-1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Ki20227, Alternative-names: , CAS# 623142-96-1, Formula: C24H24N4O5S, MWT: 480.5362, Solubility: DMSO: 7.2 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Fms, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CC-401 (hydrochloride), Alternative-names: CC401 HCl, CAS# 1438391-30-0, Formula: C22H25ClN6O, MWT: 424.9265, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: MAPK/ERK Pathway, Target: JNK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CP-724714, Alternative-names: , CAS# 383432-38-0, Formula: C27H27N5O3, MWT: 469.535, Solubility: DMSO: ≥ 50 mg/mL, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Canertinib (dihydrochloride), Alternative-names: Canertinib;CI-1033 dihydrochloride;PD-183805 dihydrochloride, CAS# 289499-45-2, Formula: C24H27Cl3FN5O3, MWT: 558.8603, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| DAPT, Alternative-names: GSI-IX, CAS# 208255-80-5, Formula: C23H26F2N2O4, MWT: 432.4604, Solubility: DMSO: ≥ 215 mg/mL, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Neuronal Signaling;Autophagy, Target: γ-secretase;γ-secretase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SRT3190, Alternative-names: SRT 3190;SRT-3190, CAS# 1204707-73-2, Formula: C18H23F2N5O4S2, MWT: 475.5331, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| URB-597, Alternative-names: KDS-4103, CAS# 546141-08-6, Formula: C20H22N2O3, MWT: 338.4003, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Neuronal Signaling;Metabolic Enzyme/Protease;Autophagy, Target: FAAH;FAAH;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Panobinostat, Alternative-names: LBH589;NVP-LBH589, CAS# 404950-80-7, Formula: C21H23N3O2, MWT: 349.4262, Solubility: DMSO: ≥ 57 mg/mL, Clinical_Information: Launched, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| VX-222, Alternative-names: VCH-222, CAS# 1026785-59-0, Formula: C25H35NO4S, MWT: 445.6147, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Pazopanib, Alternative-names: GW786034, CAS# 444731-52-6, Formula: C21H23N7O2S, MWT: 437.518, Solubility: DMSO: ≥ 43 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;Autophagy;FGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Daclatasvir (dihydrochloride), Alternative-names: BMS-790052 dihydrochloride, CAS# 1009119-65-6, Formula: C40H52Cl2N8O6, MWT: 811.7969, Solubility: DMSO: ≥ 56 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| A-867744, Alternative-names: , CAS# 1000279-69-5, Formula: C20H19ClN2O3S, MWT: 402.8945, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel;Autophagy, Target: nAChR;nAChR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| ICG-001, Alternative-names: , CAS# 847591-62-2, Formula: C33H32N4O4, MWT: 548.6316, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt, Target: Wnt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Volasertib, Alternative-names: BI 6727, CAS# 755038-65-4, Formula: C34H50N8O3, MWT: 618.8126, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage, Target: Polo-like Kinase (PLK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Zosuquidar (trihydrochloride), Alternative-names: RS 33295-198 trihydrochloride;LY-335979 trihydrochloride, CAS# 167465-36-3, Formula: C32H34Cl3F2N3O2, MWT: 636.9871, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Membrane Transporter/Ion Channel, Target: P-glycoprotein, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Vernakalant, Alternative-names: RSD1235, CAS# 794466-70-9, Formula: C20H31NO4, MWT: 349.4644, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Odanacatib, Alternative-names: MK-0822, CAS# 603139-19-1, Formula: C25H27F4N3O3S, MWT: 525.5588, Solubility: DMSO: ≥25 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: Cathepsin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Cabozantinib, Alternative-names: XL184;BMS-907351, CAS# 849217-68-1, Formula: C28H24FN3O5, MWT: 501.5057, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;VEGFR;FLT3;TAM Receptor;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Bay 60-7550, Alternative-names: BAY 607550, CAS# 439083-90-6, Formula: C27H32N4O4, MWT: 476.5674, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GW-1100, Alternative-names: , CAS# 306974-70-9, Formula: C27H25FN4O4S, MWT: 520.5752, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: GPR40, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CTS-1027, Alternative-names: RS 130830;Ro 1130830;CTS1027;CTS 1027;RS130830;Ro1130830;RS-130830;Ro-1130830, CAS# 193022-04-7, Formula: C19H20ClNO6S, MWT: 425.8832, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: MMP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TAK-875, Alternative-names: Fasiglifam, CAS# 1000413-72-8, Formula: C29H32O7S, MWT: 524.6252, Solubility: DMSO: ≥ 128 mg/mL, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: GPR40, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| ACHP (Hydrochloride), Alternative-names: , CAS# 406209-26-5, Formula: C21H25ClN4O2, MWT: 400.9018, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Silodosin, Alternative-names: KAD 3213;KMD 3213, CAS# 160970-54-7, Formula: C25H32F3N3O4, MWT: 495.5344896, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Adrenergic Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Telaprevir, Alternative-names: VX-950, CAS# 402957-28-2, Formula: C36H53N7O6, MWT: 679.8493, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Triptolide, Alternative-names: PG490, CAS# 38748-32-2, Formula: C20H24O6, MWT: 360.401, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Phase 3, Pathway: Antibody-drug Conjugate/ADC Related;Metabolic Enzyme/Protease;Cell Cycle/DNA Damage;Apoptosis, Target: ADC Cytotoxin;HSP;HSP;MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Cinacalcet, Alternative-names: AMG 073, CAS# 226256-56-0, Formula: C22H22F3N, MWT: 357.412, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: CaSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Cinacalcet (hydrochloride), Alternative-names: AMG-073 hydrochloride;Cinacalcet, CAS# 364782-34-3, Formula: C22H23ClF3N, MWT: 393.8729, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: CaSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Taranabant, Alternative-names: MK-0364, CAS# 701977-09-5, Formula: C27H25ClF3N3O2, MWT: 515.9545, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Toll-like receptor modulator, Alternative-names: Ethyl 2-amino-8-(perfluoroethyl)-3H-benzo[b]azepine-4-carboxylate, CAS# 926927-42-6, Formula: C15H13F5N2O2, MWT: 348.2679, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: Toll-like Receptor (TLR), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK-0974, Alternative-names: Telcagepant, CAS# 781649-09-0, Formula: C26H27F5N6O3, MWT: 566.523, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: GPCR/G Protein;Neuronal Signaling, Target: CGRP Receptor;CGRP Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Semagacestat, Alternative-names: LY450139, CAS# 425386-60-3, Formula: C19H27N3O4, MWT: 361.4354, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Neuronal Signaling;Stem Cell/Wnt;Neuronal Signaling;Stem Cell/Wnt, Target: Amyloid-β;γ-secretase;γ-secretase;Notch, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| E 2012, Alternative-names: , CAS# 870843-42-8, Formula: C25H26FN3O2, MWT: 419.4912, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Neuronal Signaling, Target: γ-secretase;γ-secretase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Senicapoc, Alternative-names: ICA-17043, CAS# 289656-45-7, Formula: C20H15F2NO, MWT: 323.336, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Membrane Transporter/Ion Channel, Target: Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Nutlin (3), Alternative-names: , CAS# 548472-68-0, Formula: C30H30Cl2N4O4, MWT: 581.4896, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Nutlin (3a), Alternative-names: Nutlin-3a chiral, CAS# 675576-98-4, Formula: C30H30Cl2N4O4, MWT: 581.4896, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Autophagy;Apoptosis, Target: Autophagy;MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| A-740003, Alternative-names: , CAS# 861393-28-4, Formula: C26H30N6O3, MWT: 474.5548, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: P2X Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ko 143, Alternative-names: , CAS# 461054-93-3, Formula: C26H35N3O5, MWT: 469.5732, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: BCRP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PAP-1, Alternative-names: 5-(4-Phenoxybutoxy)psoralen, CAS# 870653-45-5, Formula: C21H18O5, MWT: 350.3646, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| T863, Alternative-names: DGAT-1 inhibitor, CAS# 701232-20-4, Formula: C22H26N4O3, MWT: 394.4668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: DGAT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Glucagon receptor antagonists-1, Alternative-names: , CAS# 503559-84-0, Formula: C29H34FNO2, MWT: 447.5841632, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Glucagon Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Glucagon receptor antagonists-2, Alternative-names: , CAS# 202917-18-8, Formula: C22H30FNO2, MWT: 359.4775032, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Glucagon Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Glucagon receptor antagonists-3, Alternative-names: , CAS# 202917-17-7, Formula: C22H30FNO2, MWT: 359.4775032, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Glucagon Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GW 4064, Alternative-names: , CAS# 278779-30-9, Formula: C28H22Cl3NO4, MWT: 542.8376, Solubility: DMSO: ≥150 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: FXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| A939572, Alternative-names: stearoyl-CoA desaturase (SCD) inhibitor;SCD-inhibitor, CAS# 1032229-33-6, Formula: C20H22ClN3O3, MWT: 387.86, Solubility: DMSO: ≥ 56 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Stearoyl-CoA Desaturase (SCD), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Flavopiridol (Hydrochloride), Alternative-names: HL 275;NSC 649890;MDL 107826A;FLAVOPIRIDOL HCL;Alvocidib Hydrochloride, CAS# 131740-09-5, Formula: C21H21Cl2NO5, MWT: 438.3011, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Autophagy, Target: CDK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Calcium-Sensing Receptor Antagonists I, Alternative-names: , CAS# 478963-79-0, Formula: C23H24N2O2, MWT: 360.4489, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: CaSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| A 922500, Alternative-names: DGAT-1 Inhibitor 4a, CAS# 959122-11-3, Formula: C26H24N2O4, MWT: 428.4798, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: DGAT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LY-411575, Alternative-names: , CAS# 209984-57-6, Formula: C26H23F2N3O4, MWT: 479.4753, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Neuronal Signaling;Stem Cell/Wnt, Target: γ-secretase;γ-secretase;Notch, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| gamma-secretase modulator 2, Alternative-names: , CAS# 1093978-89-2, Formula: C25H22F4N6O2, MWT: 514.4748, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Neuronal Signaling, Target: γ-secretase;γ-secretase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| VTP-27999, Alternative-names: , CAS# 942142-51-0, Formula: C26H41ClN4O5, MWT: 525.0806, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Metabolic Enzyme/Protease, Target: Renin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| VTP-27999 (2,2,2-trifluoroacetate), Alternative-names: VTP-27999, CAS# 1013937-63-7, Formula: C28H42ClF3N4O7, MWT: 639.1038896, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Metabolic Enzyme/Protease, Target: Renin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BCX 1470, Alternative-names: Thrombin inhibitor, CAS# 217099-43-9, Formula: C14H10N2O2S2, MWT: 302.3714, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: Complement System, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BCX 1470 (methanesulfonate), Alternative-names: BCX 1470, CAS# 217099-44-0, Formula: C15H14N2O5S3, MWT: 398.4771, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: Complement System, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| ONO-AE3-208, Alternative-names: AE 3-208, CAS# 402473-54-5, Formula: C24H21FN2O3, MWT: 404.4335, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Prostaglandin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| WAY-362450, Alternative-names: XL335;Turofexorate isopropyl, CAS# 629664-81-9, Formula: C25H24F2N2O3, MWT: 438.4665, Solubility: DMSO: 15 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: FXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Enzalutamide, Alternative-names: MDV3100, CAS# 915087-33-1, Formula: C21H16F4N4O2S, MWT: 464.4359, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others;Autophagy, Target: Androgen Receptor;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| Triptonide, Alternative-names: NSC 165677;PG 492, CAS# 38647-11-9, Formula: C20H22O6, MWT: 358.3851, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Stem Cell/Wnt, Target: β-catenin;Wnt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NPS-2143, Alternative-names: SB 262470A, CAS# 284035-33-2, Formula: C24H25ClN2O2, MWT: 408.9205, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: CaSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| NPS-2143 (hydrochloride), Alternative-names: , CAS# 324523-20-8, Formula: C24H26Cl2N2O2, MWT: 445.3814, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: CaSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Plerixafor (octahydrochloride), Alternative-names: AMD3100 octahydrochloride;JM3100 octahydrochloride;SID791 octahydrochloride, CAS# 155148-31-5, Formula: C28H62Cl8N8, MWT: 794.4695, Solubility: H<sub>2</sub>O: ≥ 42 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Zaurategrast, Alternative-names: CDP323, CAS# 455264-31-0, Formula: C26H25BrN4O3, MWT: 521.4057, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cytoskeleton, Target: Integrin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Fiacitabine, Alternative-names: NSC 382097;FIAC;FOAC, CAS# 69123-90-6, Formula: C9H11FIN3O4, MWT: 371.1042, Solubility: DMSO: ≥ 37 mg/mL, Clinical_Information: Phase 2, Pathway: Anti-infection, Target: HSV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK 0893, Alternative-names: MK0893;MK-0893, CAS# 870823-12-4, Formula: C32H27Cl2N3O4, MWT: 588.4805, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: GPCR/G Protein, Target: Glucagon Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Etomoxir, Alternative-names: , CAS# 124083-20-1, Formula: C17H23ClO4, MWT: 326.8151, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Ruxolitinib (phosphate), Alternative-names: INCB018424 phosphate;INCB 018424 phosphate;INCB-018424 phosphate;Ruxolitinib, CAS# 1092939-17-7, Formula: C17H21N6O4P, MWT: 404.3602, Solubility: DMSO: ≥ 31 mg/mL; H<sub>2</sub>O: 5.4 mg/mL (Need ultrasonic or warming), Clinical_Information: Launched, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Autophagy, Target: JAK;JAK;JAK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Ruxolitinib (sulfate), Alternative-names: INCB018424 sulfateRuxolitinib, CAS# 1092939-16-6, Formula: C17H20N6O4S, MWT: 404.4435, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: JAK;JAK;JAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PDE-9 inhibitor, Alternative-names: PDE-9;PDE 9, CAS# 1082743-70-1, Formula: C22H27N5O2, MWT: 393.4821, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| gamma-secretase modulator 1, Alternative-names: , CAS# 1172637-87-4, Formula: C24H24N4OS, MWT: 416.5386, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;Neuronal Signaling, Target: γ-secretase;γ-secretase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| RG7112, Alternative-names: RO5045337, CAS# 939981-39-2, Formula: C38H48Cl2N4O4S, MWT: 727.7831, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Apoptosis, Target: MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| p53 and MDM2 proteins-interaction-inhibitor (racemic), Alternative-names: p53 inhibitor (racemic), CAS# 939983-14-9, Formula: C40H49Cl2N5O4, MWT: 734.75416, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| p53 and MDM2 proteins-interaction-inhibitor (chiral), Alternative-names: p53 inhibitor (chiral), CAS# 939981-37-0, Formula: C40H49Cl2N5O4, MWT: 734.7542, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SPK-601, Alternative-names: LMV-601, CAS# 1096687-52-3, Formula: C11H15KOS2, MWT: 266.4645, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phospholipase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TOK-001, Alternative-names: VN/124-1;Galeterone;VN 124, CAS# 851983-85-2, Formula: C26H32N2O, MWT: 388.5451, Solubility: DMSO: 18 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: Cytochrome P450, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CPA inhibitor, Alternative-names: carboxypeptidase inhibitor, CAS# 223532-02-3, Formula: C18H19NO4, MWT: 313.3477, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Carboxypeptidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| YM-155, Alternative-names: Sepantronium bromide, CAS# 781661-94-7, Formula: C20H19BrN4O3, MWT: 443.2939, Solubility: DMSO: 10.66 mg/mL, Clinical_Information: Phase 2, Pathway: Apoptosis;Autophagy, Target: Survivin;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Danoprevir, Alternative-names: ITMN-191;R7227;RO5190591;RG7227, CAS# 850876-88-9, Formula: C35H46FN5O9S, MWT: 731.8312432, Solubility: DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Simeprevir, Alternative-names: TMC435, CAS# 923604-59-5, Formula: C38H47N5O7S2, MWT: 749.9391, Solubility: DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Vaniprevir, Alternative-names: MK-7009, CAS# 923590-37-8, Formula: C38H55N5O9S, MWT: 757.9364, Solubility: DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ROCK inhibitor, Alternative-names: Rho Kinase Inhibitor;ROCK, CAS# 867017-68-3, Formula: C18H13ClF2N6O, MWT: 402.7852, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Pim1/AKK1-IN-1, Alternative-names: LKB1/AAK1 dual inhibitor, CAS# 1093222-27-5, Formula: C20H13N5O, MWT: 339.3501, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling, Target: Pim, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LY341495, Alternative-names: , CAS# 201943-63-7, Formula: C20H19NO5, MWT: 353.3686, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| MK-0812, Alternative-names: , CAS# 624733-88-6, Formula: C24H34F3N3O3, MWT: 469.5403, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Otamixaban, Alternative-names: FXV673, CAS# 193153-04-7, Formula: C25H26N4O4, MWT: 446.4984, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: Factor Xa, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| gamma-Secretase Modulators, Alternative-names: Amyloid-β production inhibitor; γ-Secretase Modulators, CAS# 937812-80-1, Formula: C26H24F3N3O3, MWT: 483.4823, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling, Target: Amyloid-β, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| INCB3344, Alternative-names: , CAS# 1262238-11-8, Formula: C29H34F3N3O6, MWT: 577.592, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MLN4924, Alternative-names: Pevonedistat, CAS# 905579-51-3, Formula: C21H25N5O4S, MWT: 443.5193, Solubility: DMSO: ≥ 111.25 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: NEDD8-activating Enzyme, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GSK256066, Alternative-names: , CAS# 801312-28-7, Formula: C27H26N4O5S, MWT: 518.5842, Solubility: DMSO: ≥ 5.2 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| SB-408124, Alternative-names: , CAS# 288150-92-5, Formula: C19H18F2N4O, MWT: 356.3692, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Orexin Receptor (OX Receptor), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK-3207 (Hydrochloride), Alternative-names: , CAS# 957116-20-0, Formula: C31H30ClF2N5O3, MWT: 594.0514, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: CGRP Receptor;CGRP Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AMD-070, Alternative-names: , CAS# 558447-26-0, Formula: C21H27N5, MWT: 349.4726, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| D149 Dye, Alternative-names: D149;Indoline dye D149, CAS# 786643-20-7, Formula: C42H35N3O4S3, MWT: 741.94, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| DMP 777, Alternative-names: L-694458, CAS# 157341-41-8, Formula: C31H40N4O6, MWT: 564.6725, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Elastase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Collagen proline hydroxylase inhibitor-1, Alternative-names: , CAS# 223663-32-9, Formula: C24H21N5O4, MWT: 443.4547, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| 3-Deazaneplanocin A, Alternative-names: NSC 617989;3-Deazaneplanocin;DZNep, CAS# 102052-95-9, Formula: C12H14N4O3, MWT: 262.2646, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Epigenetics, Target: Histone Methyltransferase;Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tozadenant, Alternative-names: SYN115, CAS# 870070-55-6, Formula: C19H26N4O4S, MWT: 406.4991, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: Adenosine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Olcegepant, Alternative-names: BIBN-4096;BIBN 4096BS, CAS# 204697-65-4, Formula: C38H47Br2N9O5, MWT: 869.6451, Solubility: DMSO: ≥ 50 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: CGRP Receptor;CGRP Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Boceprevir, Alternative-names: EBP 520;SCH 503034, CAS# 394730-60-0, Formula: C27H45N5O5, MWT: 519.6767, Solubility: DMSO: ≥ 10 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| R-1479, Alternative-names: 4'-Azidocytidine, CAS# 478182-28-4, Formula: C9H12N6O5, MWT: 284.2288, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Eldecalcitol, Alternative-names: ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3, CAS# 104121-92-8, Formula: C30H50O5, MWT: 490.715, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Sitaxsentan (sodium), Alternative-names: TBC11251 sodium salt;TBC11251, CAS# 210421-74-2, Formula: C18H14ClN2NaO6S2, MWT: 476.8863, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Fagomine, Alternative-names: D-Fagomine, CAS# 53185-12-9, Formula: C6H13NO3, MWT: 147.1723, Solubility: H<sub>2</sub>O: ≥ 36 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| SB-277011, Alternative-names: SB-277011A, CAS# 215803-78-4, Formula: C28H30N4O, MWT: 438.564, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Balapiravir, Alternative-names: Ro 4588161;R1626, CAS# 690270-29-2, Formula: C21H30N6O8, MWT: 494.4983, Solubility: DMSO: ≥ 100 mg/mL, Clinical_Information: Phase 2, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PF-04620110, Alternative-names: , CAS# 1109276-89-2, Formula: C21H24N4O4, MWT: 396.4397, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Metabolic Enzyme/Protease, Target: DGAT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Solifenacin (Succinate), Alternative-names: YM905, CAS# 242478-38-2, Formula: C27H32N2O6, MWT: 480.5528, Solubility: H<sub>2</sub>O: ≥ 200 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Decitabine, Alternative-names: NSC 127716;5-Aza-2'-deoxycytidine, CAS# 2353-33-5, Formula: C8H12N4O4, MWT: 228.2053, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Epigenetics, Target: DNA Methyltransferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Clofarabine, Alternative-names: , CAS# 123318-82-1, Formula: C10H11ClFN5O3, MWT: 303.6774, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Autophagy, Target: Nucleoside Antimetabolite/Analog;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Pentostatin, Alternative-names: Deoxycoformycin, CAS# 53910-25-1, Formula: C11H16N4O4, MWT: 268.2691, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Adenosine Deaminase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Rotigotine (Hydrochloride), Alternative-names: Rotigotine HCl, CAS# 125572-93-2, Formula: C19H26ClNOS, MWT: 351.9338, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;GPCR/G Protein;Neuronal Signaling;GPCR/G Protein, Target: Dopamine Receptor;Dopamine Receptor;Adrenergic Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Rotigotine, Alternative-names: , CAS# 99755-59-6, Formula: C19H25NOS, MWT: 315.4729, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;GPCR/G Protein;Neuronal Signaling;GPCR/G Protein, Target: Dopamine Receptor;Dopamine Receptor;Adrenergic Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| B-HT 920, Alternative-names: Talipexole dihydrochloride, CAS# 36085-73-1, Formula: C10H17Cl2N3S, MWT: 282.2331, Solubility: DMSO: < 9.4 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;GPCR/G Protein;Neuronal Signaling;GPCR/G Protein, Target: Dopamine Receptor;Dopamine Receptor;Adrenergic Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Galanthamine (hydrobromide), Alternative-names: Galantamine hydrobromide, CAS# 1953-04-4, Formula: C17H22BrNO3, MWT: 368.2655, Solubility: DMSO: ≥ 3.5 mg/mL; DMSO < 7.8 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling, Target: AChE, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Darifenacin (hydrobromide), Alternative-names: , CAS# 133099-07-7, Formula: C28H31BrN2O2, MWT: 507.4619, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
Bosentan, Alternative-names: Benzenesulfonamide, CAS# 147536-97-8, Formula: C27H29N5O6S, MWT: 551.6141, Solubility: DMSO: ≥ 275 mg/mL
, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Ramelteon, Alternative-names: TAK-375, CAS# 196597-26-9, Formula: C16H21NO2, MWT: 259.3434, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Melatonin Receptor;Melatonin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Bepotastine (Beslilate), Alternative-names: , CAS# 190786-44-8, Formula: C27H31ClN2O6S, MWT: 547.0629, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Dronedarone, Alternative-names: , CAS# 141626-36-0, Formula: C31H44N2O5S, MWT: 556.7565, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein;Autophagy, Target: mAChR;mAChR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Palonosetron, Alternative-names: , CAS# 135729-61-2, Formula: C19H24N2O, MWT: 296.4066, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Paliperidone, Alternative-names: 9-hydroxyrisperidone, CAS# 144598-75-4, Formula: C23H27FN4O3, MWT: 426.4839, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Calcipotriol, Alternative-names: MC 903;Calcipotriene, CAS# 112965-21-6, Formula: C27H40O3, MWT: 412.6047, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Calcitriol, Alternative-names: 1,25-Dihydroxyvitamin D3, CAS# 32222-06-3, Formula: C27H44O3, MWT: 416.6365, Solubility: DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Alfacalcidol, Alternative-names: 1-hydroxycholecalciferol;1.alpha.-Hydroxyvitamin D3, CAS# 41294-56-8, Formula: C27H44O2, MWT: 400.6371, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Faropenem daloxate, Alternative-names: Faropenem medoxil, CAS# 141702-36-5, Formula: C17H19NO8S, MWT: 397.39966, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Tacalcitol, Alternative-names: 1,24(R)-Dihydroxyvitamin D3;1.alpha.,24R-Dihydroxyvitamin D3, CAS# 57333-96-7, Formula: C27H44O3, MWT: 416.6365, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Maxacalcitol, Alternative-names: 22-Oxacalcitriol, CAS# 103909-75-7, Formula: C26H42O4, MWT: 418.6093, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Ercalcidiol, Alternative-names: 25-hydroxy Vitamin D2, CAS# 21343-40-8, Formula: C28H44O2, MWT: 412.6478, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ercalcitriol, Alternative-names: 1α,25-Dihydroxy Vitamin D2, CAS# 60133-18-8, Formula: C28H44O3, MWT: 428.6472, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Doxercalciferol, Alternative-names: 1.alpha.-Hydroxyvitamin D2, CAS# 54573-75-0, Formula: C28H44O2, MWT: 412.6478, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Cevimeline, Alternative-names: , CAS# 107233-08-9, Formula: C10H17NOS, MWT: 199.3131, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Seocalcitol, Alternative-names: EB 1089, CAS# 134404-52-7, Formula: C30H46O3, MWT: 454.6844, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Lexacalcitol, Alternative-names: KH 106;KH 1060, CAS# 131875-08-6, Formula: C29H48O4, MWT: 460.689, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Tacalcitol (monohydrate), Alternative-names: 1,24(R)-Dihydroxyvitamin D3 monohydrate, CAS# 93129-94-3, Formula: C27H46O4, MWT: 434.6517, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Apixaban, Alternative-names: BMS-562247-01, CAS# 503612-47-3, Formula: C25H25N5O4, MWT: 459.4971, Solubility: DMSO: 14.25 mg/mL; H<sub>2</sub>O：< 0.1 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Factor Xa, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| sitaxsentan, Alternative-names: IPI 1040;Sitax;Sitaxentan;TBC 11251, CAS# 184036-34-8, Formula: C18H15ClN2O6S2, MWT: 454.9045, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Febuxostat, Alternative-names: TEI 6720;TMX 67, CAS# 144060-53-7, Formula: C16H16N2O3S, MWT: 316.3748, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Xanthine Oxidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| CMK, Alternative-names: , CAS# 821794-90-5, Formula: C18H19ClN4O2, MWT: 358.8221, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Ribosomal S6 Kinase (RSK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| A-443654, Alternative-names: , CAS# 552325-16-3, Formula: C24H23N5O, MWT: 397.4723, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: Akt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| BMS-599626 (Hydrochloride), Alternative-names: AC480, CAS# 873837-23-1, Formula: C27H28ClFN8O3, MWT: 567.0144, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| BMS-599626, Alternative-names: AC480, CAS# 714971-09-2, Formula: C27H27FN8O3, MWT: 530.5535, Solubility: DMSO, Clinical_Information: Phase 1, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TAK-242, Alternative-names: Resatorvid, CAS# 243984-11-4, Formula: C15H17ClFNO4S, MWT: 361.8162, Solubility: DMSO: ≥ 360 mg/mL, Clinical_Information: Phase 3, Pathway: Autophagy;Immunology/Inflammation, Target: Autophagy;Toll-like Receptor (TLR), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Celastrol, Alternative-names: Tripterin, CAS# 34157-83-0, Formula: C29H38O4, MWT: 450.6096, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Autophagy, Target: Proteasome;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| MK-8245, Alternative-names: , CAS# 1030612-90-8, Formula: C17H16BrFN6O4, MWT: 467.2491, Solubility: DMSO: 19 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Stearoyl-CoA Desaturase (SCD), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Nestoron, Alternative-names: Elcometrine;Nestorone;ST-1435, CAS# 7759-35-5, Formula: C23H30O4, MWT: 370.4819, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Others, Target: Progesterone Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PNU-120596, Alternative-names: NSC 216666, CAS# 501925-31-1, Formula: C13H14ClN3O4, MWT: 311.7209, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: nAChR;nAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MRS 2578, Alternative-names: , CAS# 711019-86-2, Formula: C20H20N6S4, MWT: 472.673, Solubility: DMSO: ≥ 80 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: P2Y Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| WAY-100635 (maleate salt), Alternative-names: , CAS# 634908-75-1, Formula: C29H38N4O6, MWT: 538.6352, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| WAY-100635, Alternative-names: , CAS# 162760-96-5, Formula: C25H34N4O2, MWT: 422.563, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| PF-3845, Alternative-names: , CAS# 1196109-52-0, Formula: C24H23F3N4O2, MWT: 456.4602, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Metabolic Enzyme/Protease, Target: FAAH;FAAH, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| RU 58841, Alternative-names: , CAS# 154992-24-2, Formula: C17H18F3N3O3, MWT: 369.3383, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Androgen Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| BRL-15572 (dihydrochloride), Alternative-names: BRL-15572, CAS# 193611-72-2, Formula: C25H29Cl3N2O, MWT: 479.8696, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CGS 21680, Alternative-names: , CAS# 120225-54-9, Formula: C23H29N7O6, MWT: 499.5197, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Adenosine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| CGS 21680 (Hydrochloride), Alternative-names: , CAS# 124431-80-7, Formula: C23H30ClN7O6, MWT: 535.9806, Solubility: DMSO: ≥ 20 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Adenosine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LY2784544, Alternative-names: gandotinib, CAS# 1229236-86-5, Formula: C23H25ClFN7O, MWT: 469.9423, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: VEGFR;FLT3;JAK;JAK;JAK;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| R788(prodrug of R406), Alternative-names: Fostamatinib Disodium;R 788, CAS# 1025687-58-4, Formula: C23H24FN6Na2O9P, MWT: 624.42316376, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK, Target: Syk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ADL-5859, Alternative-names: , CAS# 850173-95-4, Formula: C24H29ClN2O3, MWT: 428.9517, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LX1606 (Hippurate), Alternative-names: Telotristat etiprate, CAS# 1137608-69-5, Formula: C36H35ClF3N7O6, MWT: 754.1546, Solubility: DMSO: ≥ 28 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Tryptophan Hydroxylase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Isobavachalcone, Alternative-names: Corylifolinin;Isobacachalcone, CAS# 20784-50-3, Formula: C20H20O4, MWT: 324.3704, Solubility: DMSO: 11 mg/mL, Clinical_Information: No Development Reported, Pathway: Autophagy, Target: Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Alendronate (sodium hydrate), Alternative-names: Alendronate;MK 217;G-704650 Adronat, CAS# 121268-17-5, Formula: C4H18NNaO10P2, MWT: 325.12371328, Solubility: H<sub>2</sub>O: ≥ 28.57 mg/mL; DMSO: < 3.2 mg/mL, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Ritonavir, Alternative-names: A 84538;ABT 538;Abbott 84538;NSC 693184;RTV, CAS# 155213-67-5, Formula: C37H48N6O5S2, MWT: 720.9442, Solubility: 10 mM in DMSO; H<sub>2</sub>O：< 0.1 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Protease;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Etravirine, Alternative-names: R165335;TMC125, CAS# 269055-15-4, Formula: C20H15BrN6O, MWT: 435.2767, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection;Anti-infection, Target: Reverse Transcriptase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| R406 (free base), Alternative-names: , CAS# 841290-80-0, Formula: C22H23FN6O5, MWT: 470.4536, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Syk, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SRT 1720, Alternative-names: , CAS# 925434-55-5, Formula: C25H23N7OS, MWT: 469.5614, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: Sirtuin;Sirtuin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GW 501516, Alternative-names: GW 1516;GSK-516, CAS# 317318-70-0, Formula: C21H18F3NO3S2, MWT: 453.4977, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Autophagy;NF-κB, Target: PPAR;Autophagy;PPAR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Elvitegravir, Alternative-names: GS-9137;JTK-303;EVG;D06677, CAS# 697761-98-1, Formula: C23H23ClFNO5, MWT: 447.8838, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Integrase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Rilpivirine, Alternative-names: R278474;TMC278, CAS# 500287-72-9, Formula: C22H18N6, MWT: 366.4185, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection;Anti-infection, Target: Reverse Transcriptase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Biperiden (Hydrochloride), Alternative-names: NSC 170950;NSC 84989, CAS# 1235-82-1, Formula: C21H30ClNO, MWT: 347.922, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Aliskiren, Alternative-names: CGP 60536;CGP60536B;SPP 100, CAS# 173334-57-1, Formula: C30H53N3O6, MWT: 551.7583, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Autophagy, Target: Renin;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ibutamoren (Mesylate), Alternative-names: MK-677;MK-0677, CAS# 159752-10-0, Formula: C28H40N4O8S2, MWT: 624.7692, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: GPCR/G Protein, Target: GHSR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Narlaprevir, Alternative-names: SCH 900518, CAS# 865466-24-6, Formula: C36H61N5O7S, MWT: 707.96384, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SD-06, Alternative-names: , CAS# 271576-80-8, Formula: C20H20ClN5O2, MWT: 397.8581, Solubility: DMSO: ≥ 29 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Ambrisentan, Alternative-names: BSF 208075;LU 208075, CAS# 177036-94-1, Formula: C22H22N2O4, MWT: 378.4211, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NVP-AEW541, Alternative-names: AEW541, CAS# 475489-16-8, Formula: C27H29N5O, MWT: 439.5521, Solubility: DMSO: ≥ 51 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: IGF-1R;Insulin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NVP-ADW742, Alternative-names: ADW742;GSK 552602A;ADW, CAS# 475488-23-4, Formula: C28H31N5O, MWT: 453.5786, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: IGF-1R, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Plerixafor, Alternative-names: AMD3100;JM3100, CAS# 110078-46-1, Formula: C28H54N8, MWT: 502.782, Solubility: Ethanol, Clinical_Information: Launched, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| LX-1031, Alternative-names: , CAS# 945976-76-1, Formula: C28H25F3N4O4, MWT: 538.5177, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Tryptophan Hydroxylase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Belinostat, Alternative-names: PXD101;PX105684, CAS# 866323-14-0, Formula: C15H14N2O4S, MWT: 318.34766, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Dolutegravir, Alternative-names: S/GSK1349572;GSK1349572, CAS# 1051375-16-6, Formula: C20H19F2N3O5, MWT: 419.3788, Solubility: DMSO: 10 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Integrase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| KX2-391 (dihydrochloride), Alternative-names: , CAS# 1038395-65-1, Formula: C26H31Cl2N3O3, MWT: 504.4486, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Cytoskeleton, Target: Src;Microtubule/Tubulin;Microtubule/Tubulin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CDK9-IN-1, Alternative-names: , CAS# 1415559-43-1, Formula: C26H21N5O4S, MWT: 499.541, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Anti-infection, Target: CDK;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| LY2979165, Alternative-names: , CAS# 1311385-32-6, Formula: C13H22N6O6S, MWT: 390.41538, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| LY2886721, Alternative-names: , CAS# 1262036-50-9, Formula: C18H16F2N4O2S, MWT: 390.407, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: Phase 2, Pathway: Neuronal Signaling, Target: Beta-secretase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LY2940680, Alternative-names: Taladegib, CAS# 1258861-20-9, Formula: C26H24F4N6O, MWT: 512.502, Solubility: DMSO: ≥ 5.2 mg/mL, Clinical_Information: Phase 2, Pathway: Stem Cell/Wnt, Target: Smo, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Omecamtiv mecarbil, Alternative-names: CK-1827452, CAS# 873697-71-3, Formula: C20H24FN5O3, MWT: 401.4347, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Cytoskeleton, Target: Myosin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| HIV-1 integrase inhibitor, Alternative-names: (Z)-4-(3-(azidomethyl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid, CAS# 544467-07-4, Formula: C11H9N3O4, MWT: 247.2069, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Integrase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| T0070907, Alternative-names: , CAS# 313516-66-4, Formula: C12H8ClN3O3, MWT: 277.6632, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Cell Cycle/DNA Damage;NF-κB, Target: PPAR;RAD51;PPAR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Glucose-conjugated MGMT inhibitor, Alternative-names: O6BTG-C8-βGlu, CAS# 382607-78-5, Formula: C24H34BrN5O7S, MWT: 616.52506, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: DNA Methyltransferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Daun02, Alternative-names: , CAS# 290304-24-4, Formula: C41H44N2O20, MWT: 884.78946, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Antibody-drug Conjugate/ADC Related, Target: Topoisomerase;ADC Cytotoxin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TAME, Alternative-names: , CAS# 901-47-3, Formula: C14H22N4O4S, MWT: 342.4139, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: APC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| OSI-420, Alternative-names: Desmethyl Erlotinib;CP-473420, CAS# 183320-51-6, Formula: C21H22ClN3O4, MWT: 415.8701, Solubility: DMSO: ≥ 4.2 mg/mL, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Thiazovivin, Alternative-names: , CAS# 1226056-71-8, Formula: C15H13N5OS, MWT: 311.3616, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| NVP-BHG712, Alternative-names: , CAS# 940310-85-0, Formula: C26H20F3N7O, MWT: 503.4785, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Ephrin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Cilomilast, Alternative-names: SB-207499, CAS# 153259-65-5, Formula: C20H25NO4, MWT: 343.4168, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| MG-132, Alternative-names: , CAS# 133407-82-6, Formula: C26H41N3O5, MWT: 475.6208, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Proteasome, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LY2603618, Alternative-names: IC-83, CAS# 911222-45-2, Formula: C18H22BrN5O3, MWT: 436.303, Solubility: DMSO: 29.5 mg/mL, Clinical_Information: Phase 2, Pathway: Autophagy;Cell Cycle/DNA Damage, Target: Autophagy;Checkpoint Kinase (Chk), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CCT128930, Alternative-names: , CAS# 885499-61-6, Formula: C18H20ClN5, MWT: 341.8379, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy, Target: Akt;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LY2157299, Alternative-names: Galunisertib, CAS# 700874-72-2, Formula: C22H19N5O, MWT: 369.4192, Solubility: DMSO: ≥ 47 mg/mL, Clinical_Information: Phase 3, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Tipifarnib, Alternative-names: IND 58359;R115777, CAS# 192185-72-1, Formula: C27H22Cl2N4O, MWT: 489.3958, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: Farnesyl Transferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TG101209, Alternative-names: , CAS# 936091-14-4, Formula: C26H35N7O2S, MWT: 509.6668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Epigenetics;Autophagy, Target: FLT3;JAK;JAK;JAK;Epigenetic Reader Domain;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| A66, Alternative-names: , CAS# 1166227-08-2, Formula: C17H23N5O2S2, MWT: 393.5268, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PCI-24781, Alternative-names: CRA 024781;CRA 24781;Abexinostat, CAS# 783355-60-2, Formula: C21H23N3O5, MWT: 397.4244, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| VX-809, Alternative-names: Lumacaftor;VRT 826809, CAS# 936727-05-8, Formula: C24H18F2N2O5, MWT: 452.4069, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: CFTR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| RO4929097, Alternative-names: , CAS# 847925-91-1, Formula: C22H20F5N3O3, MWT: 469.4045, Solubility: DMSO: ≥ 49 mg/mL, Clinical_Information: Phase 2, Pathway: Stem Cell/Wnt;Neuronal Signaling;Stem Cell/Wnt, Target: γ-secretase;γ-secretase;Notch, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CHIR-124, Alternative-names: , CAS# 405168-58-3, Formula: C23H22ClN5O, MWT: 419.9067, Solubility: DMSO: 14 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage, Target: FLT3;PDGFR;Checkpoint Kinase (Chk), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| WP1130, Alternative-names: Degrasyn, CAS# 856243-80-6, Formula: C19H18BrN3O, MWT: 384.2697, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Protein Tyrosine Kinase/RTK;Autophagy, Target: Deubiquitinase;Bcr-Abl;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ARRY-380 (analog ), Alternative-names: , CAS# 937265-83-3, Formula: C29H27N7O4S, MWT: 569.6342, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AMG 900, Alternative-names: , CAS# 945595-80-2, Formula: C28H21N7OS, MWT: 503.5776, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| A-674563, Alternative-names: , CAS# 552325-73-2, Formula: C22H22N4O, MWT: 358.4363, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: Akt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Aprepitant, Alternative-names: MK-0869;MK-869;L-754030, CAS# 170729-80-3, Formula: C23H21F7N4O3, MWT: 534.4266, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: Neurokinin Receptor;Neurokinin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| NXY-059, Alternative-names: Disufenton sodium, CAS# 168021-79-2, Formula: C11H13NNa2O7S2, MWT: 381.3329, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BS-181, Alternative-names: , CAS# 1092443-52-1, Formula: C22H32N6, MWT: 380.5297, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Droxinostat, Alternative-names: NS 41080, CAS# 99873-43-5, Formula: C11H14ClNO3, MWT: 243.6868, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Zibotentan, Alternative-names: ZD4054, CAS# 186497-07-4, Formula: C19H16N6O4S, MWT: 424.4331, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BMS-707035, Alternative-names: , CAS# 729607-74-3, Formula: C17H19FN4O5S, MWT: 410.42, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Integrase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| XAV-939, Alternative-names: , CAS# 284028-89-3, Formula: C14H11F3N2OS, MWT: 312.3102, Solubility: DMSO: 21.5 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage;Stem Cell/Wnt, Target: PARP;PARP;β-catenin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| ABT-751, Alternative-names: E7010, CAS# 141430-65-1, Formula: C18H17N3O4S, MWT: 371.4103, Solubility: DMSO: ≥ 48 mg/mL, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Cytoskeleton;Autophagy, Target: Microtubule/Tubulin;Microtubule/Tubulin;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Amonafide, Alternative-names: AS1413, CAS# 69408-81-7, Formula: C16H17N3O2, MWT: 283.3251, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage, Target: Topoisomerase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Ivacaftor, Alternative-names: VX-770, CAS# 873054-44-5, Formula: C24H28N2O3, MWT: 392.4907, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: CFTR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tubastatin A (Hydrochloride), Alternative-names: Tubastatin A HCl;TSA HCl, CAS# 1310693-92-5, Formula: C20H22ClN3O2, MWT: 371.8606, Solubility: DMSO: 10.8 mg/mL, Clinical_Information: No Development Reported, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Trichostatin A, Alternative-names: TSA, CAS# 58880-19-6, Formula: C17H22N2O3, MWT: 302.3682, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Dacomitinib, Alternative-names: PF-00299804;PF-299804, CAS# 1110813-31-4, Formula: C24H25ClFN5O2, MWT: 469.939, Solubility: DMSO: ≥ 50 mg/mL (Need ultrasonic), Clinical_Information: Phase 3, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Mocetinostat, Alternative-names: MGCD0103, CAS# 726169-73-9, Formula: C23H20N6O, MWT: 396.4445, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PTC124, Alternative-names: Ataluren, CAS# 775304-57-9, Formula: C15H9FN2O3, MWT: 284.242, Solubility: DMSO: ≥ 52 mg/mL, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: CFTR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Pralatrexate, Alternative-names: , CAS# 146464-95-1, Formula: C23H23N7O5, MWT: 477.4726, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage, Target: Antifolate, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PIK-75, Alternative-names: PIK-75 Hydrochloride, CAS# 372196-77-5, Formula: C16H15BrClN5O4S, MWT: 488.7434, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage, Target: DNA-PK;DNA-PK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| GANT 58, Alternative-names: NSC 75503, CAS# 64048-12-0, Formula: C24H16N4S, MWT: 392.4756, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt, Target: Gli, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MF63, Alternative-names: , CAS# 892549-43-8, Formula: C23H11ClN4, MWT: 378.8132, Solubility: DMSO: ≥ 43 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: PGE synthase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SRT 1720 (Hydrochloride), Alternative-names: SRT1720, CAS# 1001645-58-4, Formula: C25H24ClN7OS, MWT: 506.0224, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;Sirtuin;Sirtuin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ki16425, Alternative-names: , CAS# 355025-24-0, Formula: C23H23ClN2O5S, MWT: 474.9571, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: LPL Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Entinostat, Alternative-names: MS-275;SNDX-275, CAS# 209783-80-2, Formula: C21H20N4O3, MWT: 376.4085, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| NSC 74859, Alternative-names: S3I-201, CAS# 501919-59-1, Formula: C16H15NO7S, MWT: 365.3578, Solubility: DMSO: 25 mg/mL, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Stem Cell/Wnt, Target: STAT;STAT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SGI-1776, Alternative-names: , CAS# 1025065-69-3, Formula: C20H22F3N5O, MWT: 405.4168, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: JAK/STAT Signaling;Autophagy, Target: Pim;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Org 27569, Alternative-names: , CAS# 868273-06-7, Formula: C24H28ClN3O, MWT: 409.9516, Solubility: DMSO: ≥ 52.2 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Nepicastat, Alternative-names: SYN117;RS-25560-197, CAS# 173997-05-2, Formula: C14H15F2N3S, MWT: 295.3508, Solubility: DMSO: ≥ 48 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Dopamine β-hydroxylase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| KN-62, Alternative-names: , CAS# 127191-97-3, Formula: C38H35N5O6S2, MWT: 721.8444, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: CaMK;P2X Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| WIN 55,212-2 (Mesylate), Alternative-names: (R)-(+)-WIN 55212, CAS# 131543-23-2, Formula: C28H30N2O6S, MWT: 522.6126, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CH5424802, Alternative-names: Alectinib;AF802, CAS# 1256580-46-7, Formula: C30H34N4O2, MWT: 482.6165, Solubility: DMSO: 6.2 mg/mL (Need warming), Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK, Target: ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| VO-Ohpic (trihydrate), Alternative-names: VO-Ohpic, CAS# 476310-60-8, Formula: C12H16N2O11V+, MWT: 415.2032, Solubility: 10 mM in DMSO; H<sub>2</sub>O: < 0.1 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PTEN, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Glucocorticoid receptor agonist, Alternative-names: , CAS# 1245526-82-2, Formula: C20H20F4N2O2, MWT: 396.3786, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Glucocorticoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Cobimetinib, Alternative-names: GDC-0973;XL518, CAS# 934660-93-2, Formula: C21H21F3IN3O2, MWT: 531.31, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Canagliflozin, Alternative-names: JNJ 24831754ZAE;JNJ 28431754;JNJ 28431754AAA;TA 7284, CAS# 842133-18-0, Formula: C24H25FO5S, MWT: 444.5157, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: SGLT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| CB 300919, Alternative-names: , CAS# 289715-28-2, Formula: C32H34ClN7O2, MWT: 584.1111, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Nampt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tyrosine kinase inhibitor, Alternative-names: , CAS# 1021950-26-4, Formula: C31H31FN6O5, MWT: 586.6135, Solubility: DMSO: ≥ 46 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BMS-378806, Alternative-names: BMS-806, CAS# 357263-13-9, Formula: C22H22N4O4, MWT: 406.4345, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| NBD-556, Alternative-names: , CAS# 333353-44-9, Formula: C17H24ClN3O2, MWT: 337.8444, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NBD-557, Alternative-names: , CAS# 333352-59-3, Formula: C17H24BrN3O2, MWT: 382.2953, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AKT Kinase Inhibitor, Alternative-names: , CAS# 842148-40-7, Formula: C16H19N7O3, MWT: 357.3672, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: Akt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Dabigatran etexilate, Alternative-names: BIBR 1048, CAS# 211915-06-9, Formula: C34H41N7O5, MWT: 627.7332, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Thrombin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| RJR-2403 (oxalate), Alternative-names: (E)-Metanicotine oxalate;Rivanicline oxalate, CAS# 220662-95-3, Formula: C12H16N2O4, MWT: 252.2664, Solubility: 10 mM in H<sub>2</sub>O, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: nAChR;nAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| RJR-2403, Alternative-names: Rivanicline;Metanicotine, CAS# 15585-43-0, Formula: C10H14N2, MWT: 162.2316, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: nAChR;nAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| ASC-J9, Alternative-names: GO-Y025;Dimethylcurcumin, CAS# 52328-98-0, Formula: C23H24O6, MWT: 396.4331, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Others, Target: Androgen Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| (E)-2-Decenoic acid, Alternative-names: trans-2-Decenoic acid, CAS# 334-49-6, Formula: C10H18O2, MWT: 170.2487, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| (Z)-2-decenoic acid, Alternative-names: cis-2-Decenoic acid, CAS# 15790-91-7, Formula: C10H18O2, MWT: 170.2487, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Alvimopan, Alternative-names: ADL 8-2698;LY 246736, CAS# 156053-89-3, Formula: C25H32N2O4, MWT: 424.5326, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| JDTic, Alternative-names: , CAS# 361444-66-8, Formula: C28H39N3O3, MWT: 465.6276, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| JDTic (dihydrochloride), Alternative-names: , CAS# 785835-79-2, Formula: C28H41Cl2N3O3, MWT: 538.5494, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Laropiprant, Alternative-names: MK-0524, CAS# 571170-77-9, Formula: C21H19ClFNO4S, MWT: 435.8963, Solubility: 10 mM in DMSO, Clinical_Information: Phase 4, Pathway: GPCR/G Protein, Target: Prostaglandin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AR-C155858, Alternative-names: , CAS# 496791-37-8, Formula: C21H27N5O5S, MWT: 461.5346, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Monocarboxylate Transporter, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Dinaciclib, Alternative-names: SCH 727965, CAS# 779353-01-4, Formula: C21H28N6O2, MWT: 396.486, Solubility: DMSO: ≥ 56 mg/mL, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Silvestrol aglycone, Alternative-names: , CAS# 960365-65-5, Formula: C27H26O8, MWT: 478.4905, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Silvestrol, Alternative-names: (-)-Silvestrol, CAS# 697235-38-4, Formula: C34H38O13, MWT: 654.6577, Solubility: DMSO; H<sub>2</sub>O: < 1 mg/mL, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Caspase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Abiraterone (acetate), Alternative-names: CB7630, CAS# 154229-18-2, Formula: C26H33NO2, MWT: 391.5457, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Cytochrome P450, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Vinpocetine, Alternative-names: Ethyl apovincaminate, CAS# 42971-09-5, Formula: C22H26N2O2, MWT: 350.454, Solubility: DMSO: < 1 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Membrane Transporter/Ion Channel, Target: Phosphodiesterase (PDE);Sodium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| BAN ORL 24, Alternative-names: , CAS# 1401463-54-4, Formula: C27H37Cl2N3O2, MWT: 506.5076, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Montelukast (sodium), Alternative-names: , CAS# 151767-02-1, Formula: C35H35ClNNaO3S, MWT: 608.165, Solubility: H<sub>2</sub>O: ≥ 70 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein;Autophagy, Target: Leukotriene Receptor;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Vilazodone (Hydrochloride), Alternative-names: EMD 68843;SB659746A, CAS# 163521-08-2, Formula: C26H28ClN5O2, MWT: 477.9858, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;Neuronal Signaling;GPCR/G Protein, Target: Serotonin Transporter;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Vilazodone, Alternative-names: EMD 68843;SB659746A, CAS# 163521-12-8, Formula: C26H27N5O2, MWT: 441.5249, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;Neuronal Signaling;GPCR/G Protein, Target: Serotonin Transporter;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Ixabepilone, Alternative-names: Azaepothilone B;BMS 247550;BMS 247550-1, CAS# 219989-84-1, Formula: C27H42N2O5S, MWT: 506.6978, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Cytoskeleton, Target: Microtubule/Tubulin;Microtubule/Tubulin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Oseltamivir (acid), Alternative-names: GS 4071;Ro 64-0802;oseltamivir carboxylate, CAS# 187227-45-8, Formula: C14H24N2O4, MWT: 284.3513, Solubility: H<sub>2</sub>O: ≥ 56 mg/mL, Clinical_Information: Phase 4, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PSI-7977, Alternative-names: GS 7977;sofosbuvir, CAS# 1190307-88-0, Formula: C22H29FN3O9P, MWT: 529.4525, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Rivaroxaban, Alternative-names: BAY 59-7939, CAS# 366789-02-8, Formula: C19H18ClN3O5S, MWT: 435.8813, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Factor Xa, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Safinamide, Alternative-names: EMD 1195686;FCE 26743, CAS# 133865-89-1, Formula: C17H19FN2O2, MWT: 302.3434, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling, Target: Monoamine Oxidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| INK-128, Alternative-names: Sapanisertib;MLN0128, CAS# 1224844-38-5, Formula: C15H15N7O, MWT: 309.3259, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Anguizole, Alternative-names: , CAS# 442666-98-0, Formula: C17H11ClF2N4O2S, MWT: 408.8096, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SMND-309, Alternative-names: , CAS# 1065559-56-9, Formula: C18H14O8, MWT: 358.299, Solubility: DMSO: ≥ 3.7 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK-8033, Alternative-names: , CAS# 1001917-37-8, Formula: C25H21N5O3S, MWT: 471.5309, Solubility: DMSO: ≥ 46 mg/mL, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| JTC-801, Alternative-names: , CAS# 244218-51-7, Formula: C26H26ClN3O2, MWT: 447.9565, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CX-4945, Alternative-names: Silmitasertib, CAS# 1009820-21-6, Formula: C19H12ClN3O2, MWT: 349.7705, Solubility: DMSO: ≥ 35 mg/mL, Clinical_Information: Phase 2, Pathway: Autophagy;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: Autophagy;Casein Kinase;Casein Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Mitomycin C, Alternative-names: Ametycine, CAS# 50-07-7, Formula: C15H18N4O5, MWT: 334.3272, Solubility: DMSO: 30 mg/mL, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Autophagy, Target: DNA Alkylator/Crosslinker;ADC Cytotoxin;DNA/RNA Synthesis;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PKI-402, Alternative-names: , CAS# 1173204-81-3, Formula: C29H34N10O3, MWT: 570.6454, Solubility: DMSO: < 1 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Crenolanib, Alternative-names: CP-868596, CAS# 670220-88-9, Formula: C26H29N5O2, MWT: 443.5408, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: PDGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Pracinostat, Alternative-names: SB939, CAS# 929016-96-6, Formula: C20H30N4O2, MWT: 358.4778, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CX-5461, Alternative-names: , CAS# 1138549-36-6, Formula: C27H27N7O2S, MWT: 513.614, Solubility: DMSO: < 5.3 mg/mL, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage, Target: DNA/RNA Synthesis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Sulindac, Alternative-names: , CAS# 38194-50-2, Formula: C20H17FO3S, MWT: 356.4106, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: Launched, Pathway: Immunology/Inflammation;Autophagy, Target: COX;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| LY2109761, Alternative-names: , CAS# 700874-71-1, Formula: C26H27N5O2, MWT: 441.5249, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Autophagy;TGF-beta/Smad, Target: Autophagy;TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Tolvaptan, Alternative-names: OPC-41061, CAS# 150683-30-0, Formula: C26H25ClN2O3, MWT: 448.9413, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Autophagy, Target: Vasopressin Receptor;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Flupirtine (Maleate), Alternative-names: , CAS# 75507-68-5, Formula: C19H21FN4O6, MWT: 420.3916, Solubility: DMSO: ≥ 40 mg/mL, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel;Neuronal Signaling;Membrane Transporter/Ion Channel, Target: iGluR;iGluR;Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Suplatast (Tosilate), Alternative-names: IPD 1151T, CAS# 94055-76-2, Formula: C23H33NO7S2, MWT: 499.6406, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Launched, Pathway: Immunology/Inflammation, Target: Interleukin Related, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Saquinavir (Mesylate), Alternative-names: Ro 31-8959/003, CAS# 149845-06-7, Formula: C39H54N6O8S, MWT: 766.9465, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Autophagy;Anti-infection, Target: HIV Protease;Autophagy;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Olmesartan, Alternative-names: RNH 6270;CS 088, CAS# 144689-24-7, Formula: C24H26N6O3, MWT: 446.5016, Solubility: DMSO: ≥ 55 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Angiotensin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Olmesartan (medoxomil), Alternative-names: CS 866, CAS# 144689-63-4, Formula: C29H30N6O6, MWT: 558.5851, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Angiotensin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Caspofungin (Acetate), Alternative-names: L 743872;L 743873;MK 0991, CAS# 179463-17-3, Formula: C56H96N10O19, MWT: 1213.417, Solubility: H<sub>2</sub>O: ≥ 100 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Fungal, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PHA-848125, Alternative-names: Milciclib, CAS# 802539-81-7, Formula: C25H32N8O, MWT: 460.5746, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Autophagy, Target: CDK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Orteronel, Alternative-names: TAK-700, CAS# 566939-85-3, Formula: C18H17N3O2, MWT: 307.3465, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: Cytochrome P450, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| (+)-JQ-1, Alternative-names: JQ1, CAS# 1268524-70-4, Formula: C23H25ClN4O2S, MWT: 456.9882, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;Autophagy, Target: Epigenetic Reader Domain;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| NVP-BAG956, Alternative-names: BAG 956, CAS# 853910-02-8, Formula: C28H21N5, MWT: 427.4998, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;PDK-1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NVP-BGT226, Alternative-names: , CAS# 1245537-68-1, Formula: C32H29F3N6O6, MWT: 650.6045, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy, Target: PI3K;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Riociguat, Alternative-names: BAY 632521, CAS# 625115-55-1, Formula: C20H19FN8O2, MWT: 422.4156, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Guanylate Cyclase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BOC-D-FMK, Alternative-names: , CAS# 634911-80-1, Formula: C11H18FNO5, MWT: 263.2627, Solubility: DMSO: ≥ 125 mg/mL, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Caspase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NVP-BGJ398, Alternative-names: Infigratinib;BGJ-398, CAS# 872511-34-7, Formula: C26H31Cl2N7O3, MWT: 560.4755, Solubility: DMSO: 27 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Luliconazole, Alternative-names: NND 502, CAS# 187164-19-8, Formula: C14H9Cl2N3S2, MWT: 354.2774, Solubility: DMSO: ≥ 41 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Fungal, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Daclatasvir, Alternative-names: BMS-790052;EBP 883, CAS# 1009119-64-5, Formula: C40H50N8O6, MWT: 738.875, Solubility: DMSO: ≥ 40 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Vorinostat, Alternative-names: SAHA, CAS# 149647-78-9, Formula: C14H20N2O3, MWT: 264.3202, Solubility: DMSO: ≥ 100 mg/mL, Clinical_Information: Launched, Pathway: Autophagy;Epigenetics;Cell Cycle/DNA Damage, Target: Autophagy;HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| GDC-0980, Alternative-names: Apitolisib;GNE 390;RG 7422, CAS# 1032754-93-0, Formula: C23H30N8O3S, MWT: 498.6011, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| PF-8380, Alternative-names: , CAS# 1144035-53-9, Formula: C22H21Cl2N3O5, MWT: 478.3252, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
YM-201636, Alternative-names: , CAS# 371942-69-7, Formula: C25H21N7O3, MWT: 467.4793, Solubility: DMSO: ≥ 47 mg/mL
, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;Autophagy;PI3K/Akt/mTOR, Target: PI3K;Autophagy;PIKfyve, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Avibactam (free acid), Alternative-names: , CAS# 1192500-31-4, Formula: C7H11N3O6S, MWT: 265.2437, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| NVP-TAE 226, Alternative-names: TAE226, CAS# 761437-28-9, Formula: C23H25ClN6O3, MWT: 468.936, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Pyk2;FAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| E-7050, Alternative-names: , CAS# 928037-13-2, Formula: C33H37F2N7O4, MWT: 633.6882, Solubility: DMSO, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR;VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| R-7128, Alternative-names: RG 7128;Mericitabine;PSI 6130 diisobutyrate, CAS# 940908-79-2, Formula: C18H26FN3O6, MWT: 399.4139, Solubility: DMSO, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| PSI-6130, Alternative-names: R 1656, CAS# 817204-33-4, Formula: C10H14FN3O4, MWT: 259.2343, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Bardoxolone (methyl), Alternative-names: NSC 713200;RTA 402;CDDO Methyl ester, CAS# 218600-53-4, Formula: C32H43NO4, MWT: 505.6881, Solubility: DMSO: ≥ 49 mg/mL, Clinical_Information: Phase 3, Pathway: Autophagy;NF-κB, Target: Autophagy;Keap1-Nrf2, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| AS 602801, Alternative-names: Bentamapimod;AS602801;AS-602801, CAS# 848344-36-5, Formula: C25H23N5O2S, MWT: 457.5474, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: JNK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| JNK-IN-8, Alternative-names: , CAS# 1410880-22-6, Formula: C29H29N7O2, MWT: 507.5863, Solubility: DMSO: ≥ 35 mg/mL, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: JNK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| IRAK inhibitor 6, Alternative-names: , CAS# 1042672-97-8, Formula: C20H20N4O3S, MWT: 396.4628, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| IRAK inhibitor 1, Alternative-names: , CAS# 1042224-63-4, Formula: C17H19N5, MWT: 293.3663, Solubility: DMSO: 12.2 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| IRAK inhibitor 2, Alternative-names: , CAS# 928333-30-6, Formula: C17H14N4O2, MWT: 306.3187, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| IRAK inhibitor 3, Alternative-names: , CAS# 1012343-93-9, Formula: C21H21N5O4S, MWT: 439.4875, Solubility: DMSO: 13 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| IRAK inhibitor 4, Alternative-names: , CAS# 1012104-68-5, Formula: C33H35F3N6O3, MWT: 620.6646, Solubility: DMSO: < 10 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BMS-754807, Alternative-names: , CAS# 1001350-96-4, Formula: C23H24FN9O, MWT: 461.4948, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: IGF-1R;Insulin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SCH 527123, Alternative-names: , CAS# 473727-83-2, Formula: C21H23N3O5, MWT: 397.4244, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-4136309, Alternative-names: INCB8761, CAS# 1341224-83-6, Formula: C29H31F3N6O3, MWT: 568.5900496, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tideglusib, Alternative-names: NP-12;NP031112, CAS# 865854-05-3, Formula: C19H14N2O2S, MWT: 334.3917, Solubility: DMSO: 12.5 mg/mL, Clinical_Information: Phase 2, Pathway: Stem Cell/Wnt;PI3K/Akt/mTOR, Target: GSK-3;GSK-3, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Toltrazuril (sulfone), Alternative-names: Ponazuril, CAS# 69004-04-2, Formula: C18H14F3N3O6S, MWT: 457.3805, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Parasite , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| TH-302, Alternative-names: Evofosfamide, CAS# 918633-87-1, Formula: C9H16Br2N5O4P, MWT: 449.0362, Solubility: DMSO; H<sub>2</sub>O: 0.14 mg/mL, Clinical_Information: Phase 3, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Iguratimod, Alternative-names: T614, CAS# 123663-49-0, Formula: C17H14N2O6S, MWT: 374.3679, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation, Target: COX, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Retapamulin, Alternative-names: SB-275833, CAS# 224452-66-8, Formula: C30H47NO4S, MWT: 517.76348, Solubility: DMSO: ≥ 52 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Ticagrelor, Alternative-names: AR-C 126532XX;AZD6140, CAS# 274693-27-5, Formula: C23H28F2N6O4S, MWT: 522.5681, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: P2Y Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Erlotinib, Alternative-names: NSC 718781;OSI-744;R1415, CAS# 183321-74-6, Formula: C22H23N3O4, MWT: 393.4357, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy, Target: EGFR;EGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Palonosetron (Hydrochloride), Alternative-names: , CAS# 135729-62-3, Formula: C19H25ClN2O, MWT: 332.8676, Solubility: DMSO: 6.8 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Collagen proline hydroxylase inhibitor, Alternative-names: , CAS# 223666-07-7, Formula: C18H18N4O4, MWT: 354.3599, Solubility: DMSO: 13.15 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Bay 65-1942 (hydrochloride), Alternative-names: , CAS# 600734-06-3, Formula: C22H26ClN3O4, MWT: 431.9125, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Bay 65-1942 (free base), Alternative-names: , CAS# 600734-02-9, Formula: C22H25N3O4, MWT: 395.4516, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Avosentan, Alternative-names: Ro 67-0565;SPP-301, CAS# 290815-26-8, Formula: C23H21N5O5S, MWT: 479.5083, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Bexarotene, Alternative-names: , CAS# 153559-49-0, Formula: C24H28O2, MWT: 348.4779, Solubility: DMSO: ≥60 mg/mL (Need ultrasonic), Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Autophagy, Target: RAR/RXR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| MEK162, Alternative-names: Binimetinib;ARRY-162;ARRY-438162, CAS# 606143-89-9, Formula: C17H15BrF2N4O3, MWT: 441.2268, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Autophagy;MAPK/ERK Pathway, Target: Autophagy;MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Geldanamycin, Alternative-names: , CAS# 30562-34-6, Formula: C29H40N2O9, MWT: 560.6359, Solubility: DMSO: ≥ 24 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Flumazenil, Alternative-names: Ro 15-1788, CAS# 78755-81-4, Formula: C15H14FN3O3, MWT: 303.2884, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: GABA Receptor;GABA Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| PSI-6206, Alternative-names: RO 2433;RO2433;RO-2433, CAS# 863329-66-2, Formula: C10H13FN2O5, MWT: 260.219, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Zanamivir, Alternative-names: , CAS# 139110-80-8, Formula: C12H20N4O7, MWT: 332.3098, Solubility: H<sub>2</sub>O: ≥ 33.33 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Azaphen, Alternative-names: Azafen;Pipofezin hydrochloride;Pipofezine hydrochloride, CAS# 24853-80-3, Formula: C16H21Cl2N5O, MWT: 370.2768, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling, Target: Serotonin Transporter, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Cyclopamine, Alternative-names: 11-Deoxojervine, CAS# 4449-51-8, Formula: C27H41NO2, MWT: 411.6199, Solubility: DMSO: 0.32 mg/mL (Need ultrasonic), Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt, Target: Hedgehog, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SB 271046 (Hydrochloride), Alternative-names: SB 271046A, CAS# 209481-24-3, Formula: C20H23Cl2N3O3S2, MWT: 488.4509, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Rifabutin, Alternative-names: , CAS# 72559-06-9, Formula: C46H62N4O11, MWT: 847.0047, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Anacetrapib, Alternative-names: MK-0859, CAS# 875446-37-0, Formula: C30H25F10NO3, MWT: 637.5084, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: CETP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Linagliptin, Alternative-names: BI 1356, CAS# 668270-12-0, Formula: C25H28N8O2, MWT: 472.5422, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Dipeptidyl Peptidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Peramivir, Alternative-names: RWJ-270201;BCX-1812, CAS# 330600-85-6, Formula: C15H28N4O4, MWT: 328.4072, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Alosetron (Hydrochloride(1:X)), Alternative-names: GR 68755;GR 68755X, CAS# 132414-02-9, Formula: C17H19ClN4O, MWT: 330.81196, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Alosetron, Alternative-names: GR 68755;GR 68755X, CAS# 122852-42-0, Formula: C17H18N4O, MWT: 294.351, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Alosetron ((Z)-2-butenedioate), Alternative-names: GR 68755;GR 68755X, CAS# 122852-43-1, Formula: C21H22N4O5, MWT: 410.4232, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Alosetron (Hydrochloride), Alternative-names: GR 68755C;GR 68755;GR 68755X, CAS# 122852-69-1, Formula: C17H19ClN4O, MWT: 330.812, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Gemcitabine, Alternative-names: NSC 613327;LY188011, CAS# 95058-81-4, Formula: C9H11F2N3O4, MWT: 263.1982, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Cell Cycle/DNA Damage;Autophagy, Target: Nucleoside Antimetabolite/Analog;DNA/RNA Synthesis;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Clozapine, Alternative-names: HF 1854, CAS# 5786-21-0, Formula: C18H19ClN4, MWT: 326.8233, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| Rimonabant, Alternative-names: SR141716, CAS# 168273-06-1, Formula: C22H21Cl3N4O, MWT: 463.7874, Solubility: 10 mM in DMSO, Clinical_Information: Phase 4, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| (R)-(-)-JQ1 Enantiomer, Alternative-names: , CAS# 1268524-71-5, Formula: C23H25ClN4O2S, MWT: 456.9882, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| EMD-1214063, Alternative-names: Tepotinib, CAS# 1100598-32-0, Formula: C29H28N6O2, MWT: 492.5716, Solubility: DMSO: 27 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: c-Met/HGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| FMK, Alternative-names: RSK2 kinase inhibitor, CAS# 821794-92-7, Formula: C18H19FN4O2, MWT: 342.3675, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Ribosomal S6 Kinase (RSK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| SU14813 (maleate), Alternative-names: , CAS# 849643-15-8, Formula: C27H31FN4O8, MWT: 558.5554, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;PDGFR;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Saxagliptin, Alternative-names: BMS-477118, CAS# 361442-04-8, Formula: C18H25N3O2, MWT: 315.41, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Dipeptidyl Peptidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Retaspimycin, Alternative-names: IPI-504, CAS# 857402-23-4, Formula: C31H45N3O8, MWT: 587.7043, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Retaspimycin (Hydrochloride), Alternative-names: IPI-504, CAS# 857402-63-2, Formula: C31H46ClN3O8, MWT: 624.16524, Solubility: DMSO: ≥ 56 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Tamibarotene, Alternative-names: Am 80, CAS# 94497-51-5, Formula: C22H25NO3, MWT: 351.4388, Solubility: DMSO: 25.5 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: RAR/RXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Epothilone D, Alternative-names: 12,13-Desoxyepothilone B;Desoxyepothilone B;KOS 862, CAS# 189453-10-9, Formula: C27H41NO5S, MWT: 491.6831, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Cytoskeleton, Target: Microtubule/Tubulin;Microtubule/Tubulin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Clopidogrel, Alternative-names: , CAS# 113665-84-2, Formula: C16H16ClNO2S, MWT: 321.8217, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: P2Y Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Prasugrel, Alternative-names: , CAS# 150322-43-3, Formula: C20H20FNO3S, MWT: 373.4411, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: P2Y Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Evacetrapib, Alternative-names: LY2484595, CAS# 1186486-62-3, Formula: C31H36F6N6O2, MWT: 638.647, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: CETP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| EMD638683 (R-Form), Alternative-names: , CAS# 1184940-47-3, Formula: C18H18F2N2O4, MWT: 364.3433, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: SGK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| EMD638683 (S-Form), Alternative-names: , CAS# 1184940-46-2, Formula: C18H18F2N2O4, MWT: 364.3433, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: SGK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| ST-836, Alternative-names: , CAS# 1148156-63-1, Formula: C23H34N4OS, MWT: 414.6073, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BYL-719, Alternative-names: Alpelisib, CAS# 1217486-61-7, Formula: C19H22F3N5O2S, MWT: 441.4704896, Solubility: DMSO: ≥ 40 mg/mL, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Ciproxifan, Alternative-names: FUB-359, CAS# 184025-18-1, Formula: C16H18N2O2, MWT: 270.3263, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Pitolisant, Alternative-names: Tiprolisant, CAS# 362665-56-3, Formula: C17H26ClNO, MWT: 295.8474, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| YK-4-279, Alternative-names: , CAS# 1037184-44-3, Formula: C17H13Cl2NO4, MWT: 366.1954, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA/RNA Synthesis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Poloxin, Alternative-names: , CAS# 321688-88-4, Formula: C18H19NO3, MWT: 297.3484, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Polo-like Kinase (PLK), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LDN193189, Alternative-names: DM-3189, CAS# 1062368-24-4, Formula: C25H22N6, MWT: 406.4824, Solubility: Ethanol: 0.25 mg/mL (Need ultrasonic and warming); DMSO: < 0.1 mg/mL; H<sub>2</sub>O: < 0.1 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| LDN193189 (Hydrochloride), Alternative-names: , CAS# 1062368-62-0, Formula: C25H23ClN6, MWT: 442.94332, Solubility: H<sub>2</sub>O: 20 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Apremilast, Alternative-names: CC-10004, CAS# 608141-41-9, Formula: C22H24N2O7S, MWT: 460.5002, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Tegobuvir, Alternative-names: GS 333126;GS-9190, CAS# 1000787-75-6, Formula: C25H14F7N5, MWT: 517.401, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Adoprazine, Alternative-names: SLV313, CAS# 222551-17-9, Formula: C24H24FN3O2, MWT: 405.4647, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: GPCR/G Protein;Neuronal Signaling;Neuronal Signaling;GPCR/G Protein, Target: Dopamine Receptor;Dopamine Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Asunaprevir, Alternative-names: BMS-650032, CAS# 630420-16-5, Formula: C35H46ClN5O9S, MWT: 748.28584, Solubility: DMSO: ≥ 42.9 mg/mL, Clinical_Information: Phase 4, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HCV Protease;HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| PI3kδ inhibitor 1, Alternative-names: , CAS# 1332075-63-4, Formula: C28H33FN6O2, MWT: 504.599, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tonabersat, Alternative-names: SB-220453, CAS# 175013-84-0, Formula: C20H19ClFNO4, MWT: 391.8206, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cytoskeleton, Target: Gap Junction Protein, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Adarotene, Alternative-names: ST1926, CAS# 496868-77-0, Formula: C25H26O3, MWT: 374.4721, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK-2894, Alternative-names: , CAS# 1006036-87-8, Formula: C25H22F3NO3S, MWT: 473.5073, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Prostaglandin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK-2894 (sodium salt), Alternative-names: , CAS# 1006036-88-9, Formula: C25H21F3NNaO3S, MWT: 495.4891, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Prostaglandin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Salirasib, Alternative-names: S-Farnesylthiosalicylic acid;Farnesyl Thiosalicylic Acid;FTS, CAS# 162520-00-5, Formula: C22H30O2S, MWT: 358.5374, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Autophagy;GPCR/G Protein, Target: Autophagy;Ras, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| TMC353121, Alternative-names: , CAS# 857066-90-1, Formula: C32H42N6O3, MWT: 558.7143, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: RSV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Glyoxalase I inhibitor, Alternative-names: , CAS# 221174-33-0, Formula: C21H30BrClN4O8S, MWT: 613.9069, Solubility: DMSO: ≥ 37 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-03814735, Alternative-names: , CAS# 942487-16-3, Formula: C23H25F3N6O2, MWT: 474.4788, Solubility: DMSO: ≥ 47 mg/mL, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Epigenetics, Target: VEGFR;Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| HIV-1 integrase inhibitor 2, Alternative-names: , CAS# 957890-42-5, Formula: C21H20ClNO2, MWT: 353.842, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Integrase;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Macitentan, Alternative-names: ACT-064992, CAS# 441798-33-0, Formula: C19H20Br2N6O4S, MWT: 588.2729, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Endothelin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tedizolid, Alternative-names: DA-7157;Torezolid;TR 700, CAS# 856866-72-3, Formula: C17H15FN6O3, MWT: 370.3378, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Radezolid, Alternative-names: RX-1741, CAS# 869884-78-6, Formula: C22H23FN6O3, MWT: 438.4548, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Nesbuvir, Alternative-names: HCV-796, CAS# 691852-58-1, Formula: C22H23FN2O5S, MWT: 446.4918, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Dipraglurant, Alternative-names: ADX48621, CAS# 872363-17-2, Formula: C16H12FN3, MWT: 265.285, Solubility: DMSO: ≥ 40 mg/mL, Clinical_Information: Phase 2, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| BIBX 1382, Alternative-names: Falnidamol, CAS# 196612-93-8, Formula: C18H19ClFN7, MWT: 387.8418, Solubility: DMSO: ≥ 41 mg/mL, Clinical_Information: Phase 1, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Dabrafenib, Alternative-names: GSK2118436A;GSK2118436, CAS# 1195765-45-7, Formula: C23H20F3N5O2S2, MWT: 519.5624, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Launched, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| ZM 336372, Alternative-names: , CAS# 208260-29-1, Formula: C23H23N3O3, MWT: 389.447, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Apatinib, Alternative-names: YN968D1, CAS# 1218779-75-9, Formula: C25H27N5O4S, MWT: 493.578, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GSK1838705A, Alternative-names: , CAS# 1116235-97-2, Formula: C27H29FN8O3, MWT: 532.5693, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: IGF-1R;Insulin Receptor;ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| MK-5108, Alternative-names: VX-689, CAS# 1010085-13-8, Formula: C22H21ClFN3O3S, MWT: 461.9368432, Solubility: DMSO: 6.4 mg/mL (Need warming), Clinical_Information: Phase 1, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ganetespib, Alternative-names: STA-9090, CAS# 888216-25-9, Formula: C20H20N4O3, MWT: 364.3978, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| WYE-687, Alternative-names: , CAS# 1062161-90-3, Formula: C28H32N8O3, MWT: 528.6055, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| AT7519 (Hydrochloride), Alternative-names: , CAS# 902135-91-5, Formula: C16H18Cl3N5O2, MWT: 418.7054, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GDC-0349, Alternative-names: , CAS# 1207360-89-1, Formula: C24H32N6O3, MWT: 452.5493, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AZD2014, Alternative-names: Vistusertib, CAS# 1009298-59-2, Formula: C25H30N6O3, MWT: 462.5441, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;Autophagy, Target: mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AIM-100, Alternative-names: , CAS# 873305-35-2, Formula: C23H21N3O2, MWT: 371.4317, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: Ack1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| IRAK-1-4 Inhibitor I, Alternative-names: IRAK-1/4 Inhibitor I, CAS# 509093-47-4, Formula: C20H21N5O4, MWT: 395.41184, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;Protein Tyrosine Kinase/RTK, Target: IRAK;IRAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Paricalcitol, Alternative-names: , CAS# 131918-61-1, Formula: C27H44O3, MWT: 416.6365, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CCT 137690, Alternative-names: , CAS# 1095382-05-0, Formula: C26H31BrN8O, MWT: 551.4813, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Rimonabant (Hydrochloride), Alternative-names: SR 141716A;SR 151716A, CAS# 158681-13-1, Formula: C22H22Cl4N4O, MWT: 500.2483, Solubility: 10 mM in DMSO, Clinical_Information: Phase 4, Pathway: Autophagy;GPCR/G Protein, Target: Autophagy;Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Quetiapine (fumarate), Alternative-names: , CAS# 111974-72-2, Formula: C23H27N3O4S, MWT: 441.54, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;Neuronal Signaling;GPCR/G Protein, Target: Dopamine Receptor;Dopamine Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| PDK1 inhibitor, Alternative-names: , CAS# 1001409-50-2, Formula: C28H22F2N4O4, MWT: 516.4955, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PDK-1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CZC24832, Alternative-names: , CAS# 1159824-67-5, Formula: C15H17FN6O2S, MWT: 364.3979, Solubility: DMSO: ≥ 53 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BEZ235 (Tosylate), Alternative-names: NVP-BEZ 235 Tosylate, CAS# 1028385-32-1, Formula: C37H31N5O4S, MWT: 641.7382, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR;Autophagy, Target: PI3K;mTOR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Dronedarone (Hydrochloride), Alternative-names: , CAS# 141625-93-6, Formula: C31H45ClN2O5S, MWT: 593.2174, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Autophagy;Membrane Transporter/Ion Channel, Target: Autophagy;Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Besifloxacin (Hydrochloride), Alternative-names: , CAS# 405165-61-9, Formula: C19H22Cl2FN3O3, MWT: 430.3007, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Epothilone B, Alternative-names: EPO 906;Patupilone, CAS# 152044-54-7, Formula: C27H41NO6S, MWT: 507.6825, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage;Cytoskeleton, Target: Microtubule/Tubulin;Microtubule/Tubulin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Acamprosate (calcium), Alternative-names: Calcium N-acetylhomotaurinate, CAS# 77337-73-6, Formula: C5H10NO4S . 1/2 Ca, MWT: 200.24, Solubility: H<sub>2</sub>O: ≥ 100 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: GABA Receptor;GABA Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Anastrozole, Alternative-names: ZD1033, CAS# 120511-73-1, Formula: C17H19N5, MWT: 293.36626, Solubility: DMSO: ≥ 150 mg/mL, Clinical_Information: Launched, Pathway: Others, Target: Aromatase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| GSK 525762A, Alternative-names: I-BET 762;Molibresib, CAS# 1260907-17-2, Formula: C22H22ClN5O2, MWT: 423.8954, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Avermectin B1a, Alternative-names: Abamectin B1a, CAS# 65195-55-3, Formula: C48H72O14, MWT: 873.0769, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Parasite , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Ivermectin, Alternative-names: 22,23-Dihydroavermectin B1, CAS# 70288-86-7, Formula: C48H74O14, MWT: 875.09, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Autophagy;Anti-infection, Target: Autophagy;Parasite , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| Avermectin B1, Alternative-names: Abamectin;Avermectin B1a-Avermectin B1b mixt., CAS# 71751-41-2, Formula: C95H142O28, MWT: 1732.127, Solubility: DMSO: ≥ 247 mg/mL, Clinical_Information: Phase 3, Pathway: Autophagy;Anti-infection, Target: Autophagy;Parasite , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Tariquidar, Alternative-names: XR9576, CAS# 206873-63-4, Formula: C38H38N4O6, MWT: 646.7315, Solubility: DMSO: ≥ 100 mg/mL, Clinical_Information: Phase 3, Pathway: Membrane Transporter/Ion Channel, Target: P-glycoprotein, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| sodium 4-pentynoate, Alternative-names: , CAS# 101917-30-0, Formula: C5H5NaO2, MWT: 120.0818, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Baricitinib, Alternative-names: INCB028050;LY3009104, CAS# 1187594-09-7, Formula: C16H17N7O2S, MWT: 371.4169, Solubility: DMSO: 25 mg/mL, Clinical_Information: Launched, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: JAK;JAK;JAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Regorafenib (Hydrochloride), Alternative-names: BAY73-4506 hydrochloride, CAS# 835621-07-3, Formula: C21H16Cl2F4N4O3, MWT: 519.2764, Solubility: DMSO: ≥ 5.6 mg/mL, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Autophagy, Target: VEGFR;Raf;PDGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| RI-1, Alternative-names: , CAS# 415713-60-9, Formula: C14H11Cl3N2O3, MWT: 361.6077, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: RAD51, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Nutlin (3b), Alternative-names: Nutlin-3b, CAS# 675576-97-3, Formula: C30H30Cl2N4O4, MWT: 581.4896, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: MDM-2/p53, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Bardoxolone, Alternative-names: CDDO;RTA 401, CAS# 218600-44-3, Formula: C31H41NO4, MWT: 491.66154, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: NF-κB, Target: Keap1-Nrf2, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Aliskiren (hemifumarate), Alternative-names: CGP 60536;CGP60536B;SPP 100, CAS# 173334-58-2, Formula: C64H110N6O16, MWT: 1219.589, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Autophagy, Target: Renin;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| 5-R-Rivaroxaban, Alternative-names: BAY 59-7939, CAS# 865479-71-6, Formula: C19H18ClN3O5S, MWT: 435.8813, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Factor Xa, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SBE-β-CD, Alternative-names: Sulfobutylether-β-Cyclodextrin, CAS# 182410-00-0, Formula: C50H84Na2O41S2, MWT: 1451.28689856, Solubility: H<sub>2</sub>O: ≥ 33 mg/mL; DMSO: 5.625 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Peramivir (trihydrate), Alternative-names: RWJ 270201 trihydrate;BCX 1812 trihydrate, CAS# 1041434-82-5, Formula: C15H34N4O7, MWT: 382.4531, Solubility: H<sub>2</sub>O: 6.6 mg/mL (Need ultrasonic), Clinical_Information: Launched, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Rocuronium, Alternative-names: , CAS# 143558-00-3, Formula: C32H53N2O4+, MWT: 529.7737, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Medetomidine, Alternative-names: , CAS# 86347-14-0, Formula: C13H16N2, MWT: 200.2795, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Adrenergic Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BD-AcAc 2, Alternative-names: Ketone Ester, CAS# 1208313-97-6, Formula: C8H16O4, MWT: 176.2102, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Doramectin, Alternative-names: , CAS# 117704-25-3, Formula: C50H74O14, MWT: 899.1141, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Parasite , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Istradefylline, Alternative-names: KW-6002, CAS# 155270-99-8, Formula: C20H24N4O4, MWT: 384.429, Solubility: DMSO: < 6 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Adenosine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| CCT241533, Alternative-names: , CAS# 1262849-73-9, Formula: C23H27FN4O4, MWT: 442.4833, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Checkpoint Kinase (Chk), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Naphthoquine (phosphate), Alternative-names: , CAS# 173531-58-3, Formula: C24H34ClN3O9P2, MWT: 605.942, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Parasite , HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Agomelatine, Alternative-names: , CAS# 138112-76-2, Formula: C15H17NO2, MWT: 243.301, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BAY 80-6946, Alternative-names: Copanlisib, CAS# 1032568-63-0, Formula: C23H28N8O4, MWT: 480.5196, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Cobicistat, Alternative-names: GS-9350, CAS# 1004316-88-4, Formula: C40H53N7O5S2, MWT: 776.0227, Solubility: DMSO: ≥ 29 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Cytochrome P450, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Episilvestrol, Alternative-names: , CAS# 697235-39-5, Formula: C34H38O13, MWT: 654.6577, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Apoptosis, Target: Apoptosis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Indacaterol, Alternative-names: , CAS# 312753-06-3, Formula: C24H28N2O3, MWT: 392.4907, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Adrenergic Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| MBX-2982, Alternative-names: , CAS# 1037792-44-1, Formula: C22H24N8OS, MWT: 448.5439, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: GPCR/G Protein, Target: GPR119, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| TAK-438, Alternative-names: Vonoprazan Fumarate, CAS# 1260141-27-2, Formula: C21H20FN3O6S, MWT: 461.4634, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: Proton Pump, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GSK2636771, Alternative-names: , CAS# 1372540-25-4, Formula: C22H22F3N3O3, MWT: 433.4235896, Solubility: DMSO: 10.6 mg/mL, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| A-803467, Alternative-names: , CAS# 944261-79-4, Formula: C19H16ClNO4, MWT: 357.7876, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Sodium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Darunavir, Alternative-names: TMC114, CAS# 206361-99-1, Formula: C27H37N3O7S, MWT: 547.6636, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Protease;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Darunavir (Ethanolate), Alternative-names: TMC114, CAS# 635728-49-3, Formula: C29H43N3O8S, MWT: 593.732, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Protease;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MLN 2480, Alternative-names: BIIB-024, CAS# 1096708-71-2, Formula: C17H12Cl2F3N7O2S, MWT: 506.2890896, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: MAPK/ERK Pathway, Target: Raf, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Lorcaserin (Hydrochloride), Alternative-names: APD356, CAS# 846589-98-8, Formula: C11H15Cl2N, MWT: 232.1495, Solubility: DMSO: ≥ 2.4 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Tropisetron (Hydrochloride), Alternative-names: SDZ-ICS 930, CAS# 105826-92-4, Formula: C17H21ClN2O2, MWT: 320.8138, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Cevimeline (hydrochloride hemihydrate), Alternative-names: , CAS# 153504-70-2, Formula: C20H35ClN2O2S2, MWT: 435.0871, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Gemcitabine (Hydrochloride), Alternative-names: LY 188011 hydrochloride, CAS# 122111-03-9, Formula: C9H12ClF2N3O4, MWT: 299.6591, Solubility: H<sub>2</sub>O: ≥ 66.66 mg/mL, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Cell Cycle/DNA Damage;Autophagy, Target: Nucleoside Antimetabolite/Analog;DNA/RNA Synthesis;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| SB-705498, Alternative-names: , CAS# 501951-42-4, Formula: C17H16BrF3N4O, MWT: 429.2343496, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Membrane Transporter/Ion Channel, Target: TRP Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GPR120 modulator 1, Alternative-names: , CAS# 1050506-75-6, Formula: C19H16ClNO4S, MWT: 389.8526, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: GPR120, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GPR120 modulator 2, Alternative-names: , CAS# 1050506-87-0, Formula: C20H18ClNO3S, MWT: 387.8798, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: GPR120, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PI-103 (Hydrochloride), Alternative-names: , CAS# 371935-79-4, Formula: C19H17ClN4O3, MWT: 384.8163, Solubility: DMSO: 4.1 mg/mL; H<sub>2</sub>O: < 4 mg/mL, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Alogliptin (Benzoate), Alternative-names: SYR 322, CAS# 850649-62-6, Formula: C25H27N5O4, MWT: 461.513, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Dipeptidyl Peptidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Methylnaltrexone (Bromide), Alternative-names: , CAS# 73232-52-7, Formula: C21H26BrNO4, MWT: 436.3394, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Naltrexone (Hydrochloride), Alternative-names: , CAS# 16676-29-2, Formula: C20H24ClNO4, MWT: 377.8618, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Opioid Receptor;Opioid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 250mg |
| Fenspiride (Hydrochloride), Alternative-names: , CAS# 5053-08-7, Formula: C15H21ClN2O2, MWT: 296.7924, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation;GPCR/G Protein;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor;Adrenergic Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| CYT387 (sulfate salt), Alternative-names: momelotinib sulfate, CAS# 1056636-06-6, Formula: C23H26N6O10S2, MWT: 610.6168, Solubility: DMSO: ≥ 6.1 mg/mL, Clinical_Information: Phase 3, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Autophagy, Target: JAK;JAK;JAK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Aripiprazole, Alternative-names: , CAS# 129722-12-9, Formula: C23H27Cl2N3O2, MWT: 448.3854, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Dexrazoxane (Hydrochloride), Alternative-names: ICRF-187 hydrochloride, CAS# 149003-01-0, Formula: C11H17ClN4O4, MWT: 304.7301, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Capecitabine, Alternative-names: , CAS# 154361-50-9, Formula: C15H22FN3O6, MWT: 359.3501, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog;DNA/RNA Synthesis, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| X-Neu5Ac, Alternative-names: X-NeuNAc, CAS# 160369-85-7, Formula: C19H21BrClN2NaO9, MWT: 559.72480928, Solubility: H<sub>2</sub>O: ≥ 200 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| M2 ion channel blocker, Alternative-names: L-Histidine, N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, methyl ester, CAS# 1190215-03-2, Formula: C18H27N3O2, MWT: 317.4259, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| MI-2, Alternative-names: Menin-MLL inhibitor 2, CAS# 1271738-62-5, Formula: C18H25N5S2, MWT: 375.5546, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MI-3, Alternative-names: Menin-MLL inhibitor 3, CAS# 1271738-59-0, Formula: C18H25N5S2, MWT: 375.5546, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: Histone Methyltransferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-3758309, Alternative-names: , CAS# 898044-15-0, Formula: C25H30N8OS, MWT: 490.6237, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cytoskeleton;Cell Cycle/DNA Damage, Target: PAK;PAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| TAK-285, Alternative-names: , CAS# 871026-44-7, Formula: C26H25ClF3N5O3, MWT: 547.9566, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| chroman 1, Alternative-names: ROCK-II inhibitor, CAS# 1273579-40-0, Formula: C24H28N4O4, MWT: 436.5035, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SLx-2119, Alternative-names: ROCK inhibitor;KD-025, CAS# 911417-87-3, Formula: C26H24N6O2, MWT: 452.5078, Solubility: DMSO: ≥ 29 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Inolitazone, Alternative-names: Efatutazone;CS-7017;RS5444, CAS# 223132-37-4, Formula: C27H26N4O4S, MWT: 502.5847, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;NF-κB, Target: PPAR;PPAR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AST 487, Alternative-names: NVP-AST 487, CAS# 630124-46-8, Formula: C26H30F3N7O2, MWT: 529.5573, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;Bcr-Abl;FLT3;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK-4827, Alternative-names: Niraparib, CAS# 1038915-60-4, Formula: C19H20N4O, MWT: 320.3883, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: Launched, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: PARP;PARP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Dapagliflozin, Alternative-names: BMS-512148, CAS# 461432-26-8, Formula: C21H25ClO6, MWT: 408.8726, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: SGLT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| E-3810, Alternative-names: Lucitanib, CAS# 1058137-23-7, Formula: C26H25N3O4, MWT: 443.4944, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: VEGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| TG 100572, Alternative-names: , CAS# 867334-05-2, Formula: C26H26ClN5O2, MWT: 475.9699, Solubility: DMSO: ≥150 mg/mL , Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TG 100572 (Hydrochloride), Alternative-names: , CAS# 867331-64-4, Formula: C26H27Cl2N5O2, MWT: 512.4309, Solubility: DMSO: ≥ 44 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TG 100801, Alternative-names: , CAS# 867331-82-6, Formula: C33H30ClN5O3, MWT: 580.076, Solubility: DMSO: 6 mg/mL (Need Ultrasonic), Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| TG 100801 (Hydrochloride), Alternative-names: , CAS# 1018069-81-2, Formula: C33H31Cl2N5O3, MWT: 616.5369, Solubility: DMSO: 5 mg/mL (Need Ultrasonic), Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;PDGFR;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| ASP3026, Alternative-names: , CAS# 1097917-15-1, Formula: C29H40N8O3S, MWT: 580.7447, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| ALK inhibitor 1, Alternative-names: , CAS# 761436-81-1, Formula: C23H28BrN7O3S, MWT: 562.4825, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Fenretinide, Alternative-names: 4-HPR;(4-Hydroxyphenyl)retinamide, CAS# 65646-68-6, Formula: C26H33NO2, MWT: 391.5457, Solubility: DMSO: ≥ 130 mg/mL, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease;Autophagy, Target: RAR/RXR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Voreloxin, Alternative-names: SNS-595;Vosaroxin;AG 7352, CAS# 175414-77-4, Formula: C18H19N5O4S, MWT: 401.4396, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage, Target: Topoisomerase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Vigabatrin, Alternative-names: γ-Vinyl-GABA, CAS# 68506-86-5, Formula: C6H11NO2, MWT: 129.157, Solubility: H<sub>2</sub>O: ≥ 52 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: GABA Receptor;GABA Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Lonafarnib, Alternative-names: Sch66336, CAS# 193275-84-2, Formula: C27H31Br2ClN4O2, MWT: 638.8217, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Autophagy;Metabolic Enzyme/Protease, Target: Autophagy;Farnesyl Transferase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MPEP (Hydrochloride), Alternative-names: , CAS# 219911-35-0, Formula: C14H12ClN, MWT: 229.7048, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MPEP, Alternative-names: , CAS# 96206-92-7, Formula: C14H11N, MWT: 193.2438, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| VU 0357121, Alternative-names: , CAS# 433967-28-3, Formula: C17H17F2NO2, MWT: 305.3192, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| ALK inhibitor 2, Alternative-names: , CAS# 761438-38-4, Formula: C23H28ClN7O3S, MWT: 518.0315, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: ALK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| ST 2825, Alternative-names: , CAS# 894787-30-5, Formula: C27H28Cl2N4O5S, MWT: 591.506, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: MyD88, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Furagin, Alternative-names: Furazidine;Furazidin, CAS# 1672-88-4, Formula: C10H8N4O5, MWT: 264.1943, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Vernakalant (Hydrochloride), Alternative-names: RSD1235 hydrochloride, CAS# 748810-28-8, Formula: C20H32ClNO4, MWT: 385.9254, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| Calcifediol, Alternative-names: 25-hydroxy Vitamin D3, CAS# 19356-17-3, Formula: C27H44O2, MWT: 400.6371, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Falecalcitriol, Alternative-names: , CAS# 83805-11-2, Formula: C27H38F6O3, MWT: 524.5792392, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| 24, 25-Dihydroxy VD2, Alternative-names: 24,25-Dihydroxy vitamin D2, CAS# 58050-55-8, Formula: C28H44O3, MWT: 428.6472, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Vitamin D4, Alternative-names: , CAS# 511-28-4, Formula: C28H46O, MWT: 398.6642, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| 1alpha-Hydroxy VD4, Alternative-names: 1α-Hydroxy vitamin D4, CAS# 143032-85-3, Formula: C28H46O2, MWT: 414.6636, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| 24, 25-Dihydroxy VD3, Alternative-names: , CAS# 40013-87-4, Formula: C27H44O3, MWT: 416.6365, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| 1alpha, 24, 25-Trihydroxy VD2, Alternative-names: , CAS# 457048-34-9, Formula: C28H44O4, MWT: 444.6465, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Calcitetrol, Alternative-names: 1α, 24, 25-Trihydroxy VD3, CAS# 72203-93-1, Formula: C27H44O4, MWT: 432.6359, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Calcitriol D6, Alternative-names: , CAS# 78782-99-7, Formula: C27H38D6O3, MWT: 422.673430668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Calcipotriol (monohydrate), Alternative-names: , CAS# 147657-22-5, Formula: C27H42O4, MWT: 430.62, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| 1alpha, 25-Dihydroxy VD2-D6, Alternative-names: , CAS# 216244-04-1, Formula: C28H38D6O3, MWT: 434.684130668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| 25-Hydroxy VD2-D6, Alternative-names: , CAS# 1262843-46-8, Formula: C28H38D6O2, MWT: 418.684730668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| VD2-D3, Alternative-names: , CAS# 1217448-46-8, Formula: C28H41D3O, MWT: 399.6668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| VD3-D6, Alternative-names: Vitamin D3-26,26,26,27,27,27-d6, CAS# 118584-54-6, Formula: C27H38D6O, MWT: 390.674630668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Alfacalcidol-D6, Alternative-names: , CAS# 1641940-94-4, Formula: C27H38D6O2, MWT: 406.674030668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Calcifediol-D6, Alternative-names: , CAS# 78782-98-6, Formula: C27H38D6O2, MWT: 406.674030668, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| NVP-BKM120 (Hydrochloride), Alternative-names: BKM120 hydrochloride, CAS# 1312445-63-8, Formula: C18H22ClF3N6O2, MWT: 446.8545, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Nortadalafil, Alternative-names: Demethyl Tadalafil, CAS# 171596-36-4, Formula: C21H17N3O4, MWT: 375.3774, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Carboxypeptidase G2 (CPG2) Inhibitor, Alternative-names: CPG2 Inhibitor, CAS# 192203-60-4, Formula: C13H15NO6S, MWT: 313.3263, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: Carboxypeptidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| (R)-5-Hydroxymethyl Tolterodine, Alternative-names: Desfesoterodine;PNU-200577, CAS# 207679-81-0, Formula: C22H31NO2, MWT: 341.487, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| L-165041, Alternative-names: , CAS# 79558-09-1, Formula: C22H26O7, MWT: 402.4377, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;NF-κB, Target: PPAR;PPAR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| I2906, Alternative-names: , CAS# 331963-29-2, Formula: C25H37N3O4, MWT: 443.57898, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Lapatinib (ditosylate), Alternative-names: GW-572016 ditosylate, CAS# 388082-77-7, Formula: C43H42ClFN4O10S3, MWT: 925.4608, Solubility: DMSO: ≥150 mg/mL, Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy, Target: EGFR;EGFR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Etodolac, Alternative-names: , CAS# 41340-25-4, Formula: C17H21NO3, MWT: 287.3535, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation, Target: COX, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| SCH 563705, Alternative-names: , CAS# 473728-58-4, Formula: C23H27N3O5, MWT: 425.4776, Solubility: DMSO: ≥30mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Chenodeoxycholic Acid, Alternative-names: CDCA, CAS# 474-25-9, Formula: C24H40O4, MWT: 392.572, Solubility: DMSO: ≥ 3.6 mg/mL, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: FXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| VTP-27999 (Hydrochloride), Alternative-names: , CAS# 1264191-73-2, Formula: C26H42Cl2N4O5, MWT: 561.5415, Solubility: H<sub>2</sub>O: ≥ 100 mg/mL, Clinical_Information: Phase 1, Pathway: Metabolic Enzyme/Protease, Target: Renin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| ENMD-2076, Alternative-names: , CAS# 934353-76-1, Formula: C21H25N7, MWT: 375.4701, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: Phase 2, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK, Target: Src;VEGFR;FLT3;PDGFR;Aurora Kinase;Aurora Kinase;FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Monomethyl auristatin E, Alternative-names: Vedotin;MMAE, CAS# 474645-27-7, Formula: C39H67N5O7, MWT: 717.97858, Solubility: DMSO: ≥ 48 mg/mL, Clinical_Information: Phase 4, Pathway: Cell Cycle/DNA Damage;Cytoskeleton;Antibody-drug Conjugate/ADC Related, Target: Microtubule/Tubulin;Microtubule/Tubulin;ADC Cytotoxin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| c-FMS inhibitor, Alternative-names: , CAS# 885704-21-2, Formula: C23H30N6O, MWT: 406.5239, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Fms, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Laquinimod, Alternative-names: ABR-215062, CAS# 248281-84-7, Formula: C19H17ClN2O3, MWT: 356.8029, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Apoptosis, Target: Caspase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NVP-LCQ195, Alternative-names: LCQ-195;AT9311, CAS# 902156-99-4, Formula: C17H19Cl2N5O4S, MWT: 460.3349, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Frentizole, Alternative-names: , CAS# 26130-02-9, Formula: C15H13N3O2S, MWT: 299.3476, Solubility: DMSO: ≥ 3 mg/mL, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling, Target: Amyloid-β, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| GW3965, Alternative-names: , CAS# 405911-09-3, Formula: C33H31ClF3NO3, MWT: 582.0523496, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: LXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| GW3965 (hydrochloride), Alternative-names: , CAS# 405911-17-3, Formula: C33H32Cl2F3NO3, MWT: 618.5132896, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: LXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Oglemilast, Alternative-names: GRC 3886, CAS# 778576-62-8, Formula: C20H13Cl2F2N3O5S, MWT: 516.3021, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-04217903 (methanesulfonate), Alternative-names: , CAS# 956906-93-7, Formula: C20H20N8O4S, MWT: 468.489, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MEK inhibitor, Alternative-names: , CAS# 334951-92-7, Formula: C26H26N4O2, MWT: 426.5103, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Calcifediol (monohydrate), Alternative-names: 25-hydroxy Vitamin D3 monohydrate, CAS# 63283-36-3, Formula: C27H46O3, MWT: 418.65234, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| KB-R7943 (mesylate), Alternative-names: KB-R7943, CAS# 182004-65-5, Formula: C17H21N3O6S2, MWT: 427.4951, Solubility: DMSO: ≥ 27 mg/mL; H<sub>2</sub>O: 4.3 mg/mL (Need warming), Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Na+/Ca2+ Exchanger, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NS309, Alternative-names: , CAS# 18711-16-5, Formula: C8H4Cl2N2O2, MWT: 231.0356, Solubility: DMSO: ≥ 50 mg/mL, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: Potassium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ML-7 (hydrochloride), Alternative-names: , CAS# 110448-33-4, Formula: C15H18ClIN2O2S, MWT: 452.7381, Solubility: DMSO: ≥ 43 mg/mL, Clinical_Information: No Development Reported, Pathway: Cytoskeleton, Target: Myosin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| RS 504393, Alternative-names: , CAS# 300816-15-3, Formula: C25H27N3O3, MWT: 417.5002, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| RS 127445, Alternative-names: MT 500, CAS# 199864-86-3, Formula: C17H17ClFN3, MWT: 317.7884, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| BML-190, Alternative-names: Indomethacin morpholinylamide;IMMA, CAS# 2854-32-2, Formula: C23H23ClN2O4, MWT: 426.8927, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| AM630, Alternative-names: , CAS# 164178-33-0, Formula: C23H25IN2O3, MWT: 504.3607, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Dye 937, Alternative-names: , CAS# 195199-04-3, Formula: C32H37IN4S, MWT: 636.6324, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: DNA Stain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Setiptiline (maleate), Alternative-names: MO-8282, CAS# 85650-57-3, Formula: C23H23NO4, MWT: 377.433, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| HOKU-81, Alternative-names: 4-Hydroxytulobuterol, CAS# 58020-43-2, Formula: C12H18ClNO2, MWT: 243.7298, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Adrenergic Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Asenapine (maleate), Alternative-names: Org 5222 maleate, CAS# 85650-56-2, Formula: C21H20ClNO5, MWT: 401.8402, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;GPCR/G Protein, Target: Adrenergic Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Asenapine, Alternative-names: Org 5222, CAS# 65576-45-6, Formula: C17H16ClNO, MWT: 285.768, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;GPCR/G Protein, Target: Adrenergic Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Fludarabine (phosphate), Alternative-names: , CAS# 75607-67-9, Formula: C10H13FN5O7P, MWT: 365.2117, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Rifaximin, Alternative-names: , CAS# 80621-81-4, Formula: C43H51N3O11, MWT: 785.87854, Solubility: DMSO: ≥ 26 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| Donepezil (Hydrochloride), Alternative-names: E2020, CAS# 120011-70-3, Formula: C24H30ClNO3, MWT: 415.9529, Solubility: DMSO: 6.2 mg/mL (Need warming), Clinical_Information: Launched, Pathway: Neuronal Signaling, Target: AChE, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Ruxolitinib, Alternative-names: INCB018424, CAS# 941678-49-5, Formula: C17H18N6, MWT: 306.365, Solubility: DMSO: ≥ 36 mg/mL; H<sub>2</sub>O: < 0.1 mg/mL, Clinical_Information: Launched, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling;Autophagy, Target: JAK;JAK;JAK;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Sodium formononetin-3'-sulfonate, Alternative-names: Sul-F, CAS# 949021-68-5, Formula: C16H11NaO7S, MWT: 370.30910928, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Lurasidone (Hydrochloride), Alternative-names: SM-13496, CAS# 367514-88-3, Formula: C28H37ClN4O2S, MWT: 529.137, Solubility: DMSO: 1 mg/mL; H<sub>2</sub>O:< 1 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;Neuronal Signaling;GPCR/G Protein, Target: Dopamine Receptor;Dopamine Receptor;5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| ARRY-520, Alternative-names: Filanesib, CAS# 885060-09-3, Formula: C20H22F2N4O2S, MWT: 420.4761, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Cytoskeleton;Cell Cycle/DNA Damage, Target: Kinesin;Kinesin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PF-04457845, Alternative-names: , CAS# 1020315-31-4, Formula: C23H20F3N5O2, MWT: 455.4324, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Neuronal Signaling;Metabolic Enzyme/Protease, Target: FAAH;FAAH, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| PF-543, Alternative-names: , CAS# 1415562-82-1, Formula: C27H31NO4S, MWT: 465.6043, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: SPHK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| 3-Deazaneplanocin A (hydrochloride), Alternative-names: DZNep hydrochloride;NSC 617989 hydrochloride;3-Deazaneplanocin hydrochloride, CAS# 120964-45-6, Formula: C12H15ClN4O3, MWT: 298.7255, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Epigenetics, Target: Histone Methyltransferase;Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Oseltamivir (phosphate), Alternative-names: GS 4104, CAS# 204255-11-8, Formula: C16H31N2O8P, MWT: 410.3997, Solubility: DMSO: ≥ 150 mg/mL; H<sub>2</sub>O: 125 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection, Target: Influenza Virus, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Bay 65-1942 (R form), Alternative-names: Bay 65-1942, CAS# 758683-21-5, Formula: C22H25N3O4, MWT: 395.4516, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: IKK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
Paradol, Alternative-names: [6]-Gingerone;[6]-Paradol, CAS# 27113-22-0, Formula: C17H26O3, MWT: 278.3865, Solubility: DMSO: ≥ 140 mg/mL
, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: COX, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Umeclidinium (bromide), Alternative-names: GSK573719A, CAS# 869113-09-7, Formula: C29H34BrNO2, MWT: 508.4897, Solubility: DMSO: ≥ 34 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NG25, Alternative-names: , CAS# 1315355-93-1, Formula: C29H30F3N5O2, MWT: 537.576, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: NF-κB, Target: TAK1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| 5-hydroxypyrazine-2-carboxylic acid, Alternative-names: , CAS# 34604-60-9, Formula: C5H4N2O3, MWT: 140.0969, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Y-27632 (dihydrochloride), Alternative-names: , CAS# 129830-38-2, Formula: C14H23Cl2N3O, MWT: 320.2579, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage, Target: ROCK;ROCK;ROCK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 500mg |
| CVT-313, Alternative-names: NG26, CAS# 199986-75-9, Formula: C20H28N6O3, MWT: 400.4747, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Teneligliptin, Alternative-names: , CAS# 760937-92-6, Formula: C22H30N6OS, MWT: 426.5782, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Dipeptidyl Peptidase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| AZ3146, Alternative-names: , CAS# 1124329-14-1, Formula: C24H32N6O3, MWT: 452.5493, Solubility: DMSO: 11.75 mg/mL, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage;Cytoskeleton, Target: Mps1;Mps1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SB1317, Alternative-names: TG02, CAS# 937270-47-8, Formula: C23H24N4O, MWT: 372.4629, Solubility: DMSO: 26.5 mg/mL, Clinical_Information: Phase 2, Pathway: Cell Cycle/DNA Damage;Protein Tyrosine Kinase/RTK;Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: CDK;FLT3;JAK;JAK;JAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ARN-509, Alternative-names: Apalutamide, CAS# 956104-40-8, Formula: C21H15F4N5O2S, MWT: 477.4347, Solubility: DMSO: ≥83.3 mg/mL, Clinical_Information: Phase 3, Pathway: Others, Target: Androgen Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Cetirizine, Alternative-names: , CAS# 83881-51-0, Formula: C21H25ClN2O3, MWT: 388.8878, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Loratadine, Alternative-names: SCH 29851;Loratidine, CAS# 79794-75-5, Formula: C22H23ClN2O2, MWT: 382.8832, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Duvelisib, Alternative-names: IPI-145;INK1197, CAS# 1201438-56-3, Formula: C22H17ClN6O, MWT: 416.863, Solubility: DMSO: ≥ 41 mg/mL, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| (R)-Baclofen, Alternative-names: STX209, CAS# 69308-37-8, Formula: C10H12ClNO2, MWT: 213.6608, Solubility: H<sub>2</sub>O: 5 mg/mL (Need ultrasonic), Clinical_Information: Phase 3, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: GABA Receptor;GABA Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Pramipexole (dihydrochloride), Alternative-names: , CAS# 104632-25-9, Formula: C10H19Cl2N3S, MWT: 284.249, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein;Neuronal Signaling;Autophagy, Target: Dopamine Receptor;Dopamine Receptor;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Ispinesib, Alternative-names: SB-715992, CAS# 336113-53-2, Formula: C30H33ClN4O2, MWT: 517.0616, Solubility: DMSO: ≥ 125 mg/mL, Clinical_Information: Phase 2, Pathway: Cytoskeleton;Cell Cycle/DNA Damage, Target: Kinesin;Kinesin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Fenofibrate, Alternative-names: , CAS# 49562-28-9, Formula: C20H21ClO4, MWT: 360.8313, Solubility: DMSO: ≥ 47 mg/mL, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Autophagy;Metabolic Enzyme/Protease;NF-κB, Target: PPAR;Autophagy;Cytochrome P450;PPAR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10g |
| Choline Fenofibrate, Alternative-names: ABT-335, CAS# 856676-23-8, Formula: C22H28ClNO5, MWT: 421.9144, Solubility: DMSO: 6.2 mg/mL (Need ultrasonic and warming), Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;NF-κB, Target: PPAR;Cytochrome P450;PPAR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| BIX-01294, Alternative-names: , CAS# 935693-62-2, Formula: C28H38N6O2, MWT: 490.6403, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics;Autophagy, Target: Histone Methyltransferase;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SD-208, Alternative-names: , CAS# 627536-09-8, Formula: C17H10ClFN6, MWT: 352.7529, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: TGF-beta/Smad, Target: TGF-β Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Aclidinium (Bromide), Alternative-names: LAS 34273;LAS-W 330, CAS# 320345-99-1, Formula: C26H30BrNO4S2, MWT: 564.5547, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| 5-Iodotubercidin, Alternative-names: NSC 113939; 5-ITu, CAS# 24386-93-4, Formula: C11H13IN4O4, MWT: 392.1498, Solubility: DMSO: ≥ 49 mg/mL, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease;Neuronal Signaling, Target: Adenosine Kinase;Adenosine Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Tasquinimod, Alternative-names: ABR-215050, CAS# 254964-60-8, Formula: C20H17F3N2O4, MWT: 406.3552, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: Phase 3, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Nepafenac, Alternative-names: AHR 9434;AL 6515, CAS# 78281-72-8, Formula: C15H14N2O2, MWT: 254.2839, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: Launched, Pathway: Immunology/Inflammation, Target: COX, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Loteprednol Etabonate, Alternative-names: , CAS# 82034-46-6, Formula: C24H31ClO7, MWT: 466.9518, Solubility: DMSO: ≥ 45 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Glucocorticoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Deferasirox, Alternative-names: , CAS# 201530-41-8, Formula: C21H15N3O4, MWT: 373.3615, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| BIBR 1532, Alternative-names: , CAS# 321674-73-1, Formula: C21H17NO3, MWT: 331.3646, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Telomerase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Tiotropium (Bromide), Alternative-names: Tiopropium, CAS# 136310-93-5, Formula: C19H22BrNO4S2, MWT: 472.41628, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| LDE225, Alternative-names: NVP-LDE 225;Erismodegib, CAS# 956697-53-3, Formula: C26H26F3N3O3, MWT: 485.4981, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Stem Cell/Wnt, Target: Smo, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Etofenamate, Alternative-names: , CAS# 30544-47-9, Formula: C18H18F3NO4, MWT: 369.335, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Diphenmanil (methylsulfate), Alternative-names: Diphemanil mesylate, CAS# 62-97-5, Formula: C21H27NO4S, MWT: 389.5084, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling;GPCR/G Protein, Target: mAChR;mAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| LY2874455, Alternative-names: , CAS# 1254473-64-7, Formula: C21H19Cl2N5O2, MWT: 444.3139, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Protein Tyrosine Kinase/RTK, Target: FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Vancomycin (hydrochloride), Alternative-names: , CAS# 1404-93-9, Formula: C66H76Cl3N9O24, MWT: 1485.715, Solubility: DMSO: 24 mg/mL, Clinical_Information: Launched, Pathway: Anti-infection;Autophagy, Target: Bacterial;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Dimethyl fumarate, Alternative-names: DMF, CAS# 624-49-7, Formula: C6H8O4, MWT: 144.1253, Solubility: DMSO: 9.6 mg/mL, Clinical_Information: Launched, Pathway: NF-κB, Target: Keap1-Nrf2, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| SL327, Alternative-names: , CAS# 305350-87-2, Formula: C16H12F3N3S, MWT: 335.3467896, Solubility: 10 mM in DMSO; ethanol: 0.1 mg/mL (Need ultrasonic and warming), Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: MEK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| 17-AAG (Hydrochloride), Alternative-names: Tanespimycin Hydrochloride;NSC 330507 Hydrochloride;CP 127374 Hydrochloride, CAS# 911710-03-7, Formula: C31H44ClN3O8, MWT: 622.1494, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Autophagy;Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: Autophagy;HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Alvespimycin, Alternative-names: 17-DMAG;KOS-1022;NSC 707545, CAS# 467214-20-6, Formula: C32H48N4O8, MWT: 616.7455, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| LY2183240, Alternative-names: , CAS# 874902-19-9, Formula: C17H17N5O, MWT: 307.3498, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Neuronal Signaling;Metabolic Enzyme/Protease, Target: FAAH;FAAH, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MK-8245 (Trifluoroacetate), Alternative-names: , CAS# 1415559-41-9, Formula: C19H17BrF4N6O6, MWT: 581.2725, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Metabolic Enzyme/Protease, Target: Stearoyl-CoA Desaturase (SCD), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Mirabegron, Alternative-names: YM178, CAS# 223673-61-8, Formula: C21H24N4O2S, MWT: 396.5059, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Adrenergic Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Dalcetrapib, Alternative-names: JTT-705;RO4607381, CAS# 211513-37-0, Formula: C23H35NO2S, MWT: 389.5945, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Metabolic Enzyme/Protease, Target: CETP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GSK2334470, Alternative-names: , CAS# 1227911-45-6, Formula: C25H34N8O, MWT: 462.5905, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: PI3K/Akt/mTOR, Target: PDK-1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Icotinib (Hydrochloride), Alternative-names: BPI-2009H, CAS# 1204313-51-8, Formula: C22H22ClN3O4, MWT: 427.8808, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-04691502, Alternative-names: , CAS# 1013101-36-4, Formula: C22H27N5O4, MWT: 425.4809, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;PI3K/Akt/mTOR, Target: PI3K;mTOR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| ST-836 (hydrochloride), Alternative-names: , CAS# 1415564-68-9, Formula: C23H35ClN4OS, MWT: 451.0682, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Zosuquidar, Alternative-names: LY335979, CAS# 167354-41-8, Formula: C32H31F2N3O2, MWT: 527.6042464, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Membrane Transporter/Ion Channel, Target: P-glycoprotein, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| BMS-265246, Alternative-names: , CAS# 582315-72-8, Formula: C18H17F2N3O2, MWT: 345.3433, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: CDK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Nelfinavir (Mesylate), Alternative-names: AG 1343 Mesylate, CAS# 159989-65-8, Formula: C33H49N3O7S2, MWT: 663.8881, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Protease;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Ciproxifan (maleate), Alternative-names: FUB 359 maleate, CAS# 184025-19-2, Formula: C20H22N2O6, MWT: 386.3985, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: Histamine Receptor;Histamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| rac-Rotigotine (Hydrochloride), Alternative-names: , CAS# 102120-99-0, Formula: C19H26ClNOS, MWT: 351.9338, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Neuronal Signaling, Target: Dopamine Receptor;Dopamine Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CHAPS, Alternative-names: , CAS# 75621-03-3, Formula: C32H58N2O7S, MWT: 614.8771, Solubility: H<sub>2</sub>O: ≥ 46 mg/mL, Clinical_Information: No Development Reported, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| Voreloxin (Hydrochloride), Alternative-names: SNS-595 Hydrochloride;Vosaroxin Hydrochloride;AG 7352 Hydrochloride, CAS# 175519-16-1, Formula: C18H20ClN5O4S, MWT: 437.9005, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage, Target: Topoisomerase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
Tofacitinib (citrate), Alternative-names: Tasocitinib citrate;CP-690550 citrate, CAS# 540737-29-9, Formula: C22H28N6O8, MWT: 504.4931, Solubility: DMSO: ≥ 122.5 mg/mL
, Clinical_Information: Launched, Pathway: Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling, Target: JAK;JAK;JAK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| Secalciferol, Alternative-names: (24R)-24,25-Dihydroxyvitamin D3, CAS# 55721-11-4, Formula: C27H44O3, MWT: 416.6365, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| I-BET151, Alternative-names: GSK1210151A, CAS# 1300031-49-5, Formula: C23H21N5O3, MWT: 415.4445, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Epigenetics, Target: Epigenetic Reader Domain, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| (24S)-24,25-Dihydroxyvitamin D3, Alternative-names: (24S)-24,25-Dihydroxycholecalciferol, CAS# 55700-58-8, Formula: C27H44O3, MWT: 416.6365, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Vitamin D Related, Target: VD/VDR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1mg |
| Bazedoxifene, Alternative-names: , CAS# 198481-32-2, Formula: C30H34N2O3, MWT: 470.6026, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others, Target: Estrogen Receptor/ERR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| EVP-6124, Alternative-names: Encenicline, CAS# 550999-75-2, Formula: C16H17ClN2OS, MWT: 320.837, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: nAChR;nAChR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SB-674042, Alternative-names: , CAS# 483313-22-0, Formula: C24H21FN4O2S, MWT: 448.5125, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Orexin Receptor (OX Receptor), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AM679, Alternative-names: , CAS# 1206880-66-1, Formula: C40H44N4O5S, MWT: 692.8661, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: FLAP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| MK591, Alternative-names: Quiflapon sodium, CAS# 147030-01-1, Formula: C34H34ClN2NaO3S, MWT: 609.15312928, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: FLAP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| BMN-673, Alternative-names: Talazoparib;LT-673, CAS# 1207456-01-6, Formula: C19H14F2N6O, MWT: 380.3509, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: PARP;PARP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| BMS-626529, Alternative-names: Temsavir, CAS# 701213-36-7, Formula: C24H23N7O4, MWT: 473.4839, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: Anti-infection, Target: HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Bitopertin, Alternative-names: RG1678;RO4917838, CAS# 845614-11-1, Formula: C21H20F7N3O4S, MWT: 543.4550224, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel, Target: GlyT;GlyT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 25mg |
| Empagliflozin, Alternative-names: BI 10773, CAS# 864070-44-0, Formula: C23H27ClO7, MWT: 450.9093, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: SGLT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Skepinone-L, Alternative-names: Skepinone L, CAS# 1221485-83-1, Formula: C24H21F2NO4, MWT: 425.4247, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: MAPK/ERK Pathway, Target: p38 MAPK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| PF-04447943, Alternative-names: , CAS# 1082744-20-4, Formula: C20H25N7O2, MWT: 395.4582, Solubility: DMSO: ≥ 54.6 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Temozolomide, Alternative-names: NSC 362856;CCRG 81045;TZM, CAS# 85622-93-1, Formula: C6H6N6O2, MWT: 194.1508, Solubility: DMSO: ≥ 33.33 mg/mL, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Autophagy, Target: DNA Alkylator/Crosslinker;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Octreotide (acetate), Alternative-names: SMS 201995, CAS# 79517-01-4, Formula: C51H70N10O12S2, MWT: 1079.291, Solubility: DMSO: ≥ 29 mg/mL, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Somatostatin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Atazanavir, Alternative-names: BMS-232632, CAS# 198904-31-3, Formula: C38H52N6O7, MWT: 704.8555, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Anti-infection, Target: HIV Protease;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Rivastigmine, Alternative-names: S-Rivastigmine, CAS# 123441-03-2, Formula: C14H22N2O2, MWT: 250.3367, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling, Target: AChE, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Rivastigmine (tartrate), Alternative-names: ENA 713; SDZ-ENA 713, CAS# 129101-54-8, Formula: C18H28N2O8, MWT: 400.4235, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Neuronal Signaling, Target: AChE, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| Tirofiban (hydrochloride monohydrate), Alternative-names: , CAS# 150915-40-5, Formula: C22H39ClN2O6S, MWT: 495.0728, Solubility: DMSO: 12 mg/mL, Clinical_Information: Launched, Pathway: Cytoskeleton, Target: Integrin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Azelnidipine, Alternative-names: CS 905, CAS# 123524-52-7, Formula: C33H34N4O6, MWT: 582.6462, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Membrane Transporter/Ion Channel, Target: Calcium Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Valganciclovir, Alternative-names: , CAS# 175865-60-8, Formula: C14H22N6O5, MWT: 354.3617, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: CMV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| SB 415286, Alternative-names: , CAS# 264218-23-7, Formula: C16H10ClN3O5, MWT: 359.7207, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;PI3K/Akt/mTOR, Target: GSK-3;GSK-3, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Desmopressin (Acetate), Alternative-names: DDAVP, CAS# 62288-83-9, Formula: C48H68N14O14S2, MWT: 1129.26892, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: GPCR/G Protein, Target: Vasopressin Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 2mg |
| MK-0591, Alternative-names: Quiflapon, CAS# 136668-42-3, Formula: C34H35ClN2O3S, MWT: 587.1713, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation, Target: FLAP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| RO-9187, Alternative-names: , CAS# 876708-03-1, Formula: C9H12N6O5, MWT: 284.22878, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: HCV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| SRT 2104, Alternative-names: , CAS# 1093403-33-8, Formula: C26H24N6O2S2, MWT: 516.6378, Solubility: DMSO: < 6 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: Sirtuin;Sirtuin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
Sobetirome, Alternative-names: GC-1; QRX-431, CAS# 211110-63-3, Formula: C20H24O4, MWT: 328.4022, Solubility: DMSO: 9.85 mg/mL (Need ultrasonic)
, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: LXR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Kaempferide, Alternative-names: Kaempferol 4'-O-methyl ether, CAS# 491-54-3, Formula: C16H12O6, MWT: 300.2629, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Others;Autophagy, Target: Estrogen Receptor/ERR;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| INCB 3284 (dimesylate), Alternative-names: , CAS# 887401-93-6, Formula: C28H39F3N4O10S2, MWT: 712.7552696, Solubility: DMSO: ≥83.3 mg/mL, Clinical_Information: No Development Reported, Pathway: Immunology/Inflammation;GPCR/G Protein, Target: CCR;CCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| MDA 19, Alternative-names: , CAS# 1048973-47-2, Formula: C21H23N3O2, MWT: 349.4262, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: Cannabinoid Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| EX-527, Alternative-names: Selisistat, CAS# 49843-98-3, Formula: C13H13ClN2O, MWT: 248.7081, Solubility: DMSO: ≥ 32 mg/mL, Clinical_Information: No Development Reported, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: Sirtuin;Sirtuin, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| CPI-613, Alternative-names: , CAS# 95809-78-2, Formula: C22H28O2S2, MWT: 388.5865, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease, Target: Pyruvate Dehydrogenase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| Roflumilast, Alternative-names: , CAS# 162401-32-3, Formula: C17H14Cl2F2N2O3, MWT: 403.2075, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease, Target: Phosphodiesterase (PDE), HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
Imatinib, Alternative-names: STI571, CAS# 152459-95-5, Formula: C29H31N7O, MWT: 493.6028, Solubility: DMSO: 40 mg/mL
, Clinical_Information: Launched, Pathway: Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK, Target: Bcr-Abl;PDGFR;Autophagy;c-Kit, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5g |
| ACY-1215, Alternative-names: Ricolinostat;Rocilinostat, CAS# 1316214-52-4, Formula: C24H27N5O3, MWT: 433.5029, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| AT-101, Alternative-names: (R)-(-)-Gossypol;R-(-)-gossypol acetic acid, CAS# 90141-22-3, Formula: C30H30O8, MWT: 518.5544, Solubility: 10 mM in DMSO, Clinical_Information: Phase 2, Pathway: Apoptosis, Target: Bcl-2 Family, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| NVP-BVU972, Alternative-names: , CAS# 1185763-69-2, Formula: C20H16N6, MWT: 340.3812, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: c-Met/HGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Triciribine, Alternative-names: API-2;NSC 154020;TCN, CAS# 35943-35-2, Formula: C13H16N6O4, MWT: 320.304, Solubility: DMSO: ≥ 44 mg/mL, Clinical_Information: Phase 2, Pathway: PI3K/Akt/mTOR;Cell Cycle/DNA Damage;Anti-infection, Target: Akt;DNA/RNA Synthesis;HIV, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AT13387, Alternative-names: Onalespib, CAS# 912999-49-6, Formula: C24H31N3O3, MWT: 409.5212, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Phase 2, Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage, Target: HSP;HSP, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SAR131675, Alternative-names: , CAS# 1433953-83-3, Formula: C18H22N4O4, MWT: 358.3917, Solubility: DMSO: ≥ 28 mg/mL, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| AZD4547, Alternative-names: , CAS# 1035270-39-3, Formula: C26H33N5O3, MWT: 463.5719, Solubility: 10 mM in DMSO, Clinical_Information: Phase 3, Pathway: Protein Tyrosine Kinase/RTK, Target: FGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| Cabazitaxel, Alternative-names: XRP6258;RPR-116258A;taxoid XRP6258, CAS# 183133-96-2, Formula: C45H57NO14, MWT: 835.9324, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Cytoskeleton;Autophagy, Target: Microtubule/Tubulin;Microtubule/Tubulin;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 200mg |
| CHIR-090, Alternative-names: , CAS# 728865-23-4, Formula: C24H27N3O5, MWT: 437.4883, Solubility: DMSO: ≥ 30 mg/mL, Clinical_Information: No Development Reported, Pathway: Anti-infection, Target: Bacterial, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CTEP, Alternative-names: mGluR5 inhibitor, CAS# 871362-31-1, Formula: C19H13ClF3N3O, MWT: 391.7742, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein, Target: mGluR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GDC-0068, Alternative-names: Ipatasertib;RG7440, CAS# 1001264-89-6, Formula: C24H32ClN5O2, MWT: 457.9962, Solubility: DMSO: ≥ 28 mg/mL, Clinical_Information: Phase 3, Pathway: PI3K/Akt/mTOR, Target: Akt, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PF-04971729, Alternative-names: Ertugliflozin, CAS# 1210344-57-2, Formula: C22H25ClO7, MWT: 436.8827, Solubility: DMSO: ≥ 46 mg/mL, Clinical_Information: Phase 3, Pathway: Membrane Transporter/Ion Channel, Target: SGLT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| SRT3109, Alternative-names: , CAS# 1204707-71-0, Formula: C18H23F2N5O4S2, MWT: 475.5331, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: GPCR/G Protein;Immunology/Inflammation, Target: CXCR;CXCR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AZD1152, Alternative-names: Barasertib, CAS# 722543-31-9, Formula: C26H31FN7O6P, MWT: 587.5398, Solubility: DMSO: ≥ 33 mg/mL, Clinical_Information: Phase 3, Pathway: Cell Cycle/DNA Damage;Epigenetics, Target: Aurora Kinase;Aurora Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Repaglinide, Alternative-names: AG-EE 623ZW, CAS# 135062-02-1, Formula: C27H36N2O4, MWT: 452.5858, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Others, Target: Others, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
AMG 517, Alternative-names: , CAS# 659730-32-2, Formula: C20H13F3N4O2S, MWT: 430.4030296, Solubility: DMSO: 12.91 mg/mL (Need ultrasonic)
, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: TRP Channel, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| CH5132799, Alternative-names: , CAS# 1007207-67-1, Formula: C15H19N7O3S, MWT: 377.4214, Solubility: 10 mM in DMSO, Clinical_Information: Phase 1, Pathway: PI3K/Akt/mTOR, Target: PI3K, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| DGAT-1 inhibitor 2, Alternative-names: DGAT-1 inhibitor, CAS# 942999-61-3, Formula: C24H28N4O3, MWT: 420.5041, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: DGAT, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| AST-1306, Alternative-names: , CAS# 897383-62-9, Formula: C24H18ClFN4O2, MWT: 448.8767, Solubility: DMSO, Clinical_Information: No Development Reported, Pathway: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK, Target: EGFR;EGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Carfilzomib, Alternative-names: PR-171, CAS# 868540-17-4, Formula: C40H57N5O7, MWT: 719.9099, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Metabolic Enzyme/Protease;Autophagy, Target: Proteasome;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Romidepsin, Alternative-names: FK 228;FR 901228;NSC 630176, CAS# 128517-07-7, Formula: C24H36N4O6S2, MWT: 540.6959, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Epigenetics;Cell Cycle/DNA Damage, Target: HDAC;HDAC, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| ZM323881, Alternative-names: , CAS# 193001-14-8, Formula: C22H18FN3O2, MWT: 375.3956, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Protein Tyrosine Kinase/RTK, Target: VEGFR, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| LY2811376, Alternative-names: , CAS# 1194044-20-6, Formula: C15H14F2N4S, MWT: 320.3603, Solubility: DMSO: ≥ 31 mg/mL, Clinical_Information: Phase 1, Pathway: Neuronal Signaling, Target: Beta-secretase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 10mg |
| IOX2, Alternative-names: , CAS# 931398-72-0, Formula: C19H16N2O5, MWT: 352.3407, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Metabolic Enzyme/Protease, Target: HIF/HIF Prolyl-Hydroxylase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| GW791343 (dihydrochloride), Alternative-names: , CAS# 1019779-04-4, Formula: C20H26Cl2F2N4O, MWT: 447.3495, Solubility: DMSO: ≥ 42 mg/mL, Clinical_Information: No Development Reported, Pathway: Membrane Transporter/Ion Channel, Target: P2X Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| PRX-08066, Alternative-names: , CAS# 866206-54-4, Formula: C19H17ClFN5S, MWT: 401.8882, Solubility: DMSO: 7 mg/mL (Need ultrasonic), Clinical_Information: Phase 2, Pathway: Neuronal Signaling;GPCR/G Protein, Target: 5-HT Receptor;5-HT Receptor, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Oxaliplatin, Alternative-names: , CAS# 61825-94-3, Formula: C8H14N2O4Pt, MWT: 397.29176, Solubility: DMSO: 32 mg/mL (Need ultrasonic), Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage;Autophagy, Target: DNA Alkylator/Crosslinker;Autophagy, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 50mg |
| 5-Fluorouracil, Alternative-names: 5-FU, CAS# 51-21-8, Formula: C4H3FN2O2, MWT: 130.0772, Solubility: DMSO: 15 mg/mL, Clinical_Information: Launched, Pathway: Cell Cycle/DNA Damage, Target: Nucleoside Antimetabolite/Analog, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 1g |
| CHR-6494, Alternative-names: , CAS# 1333377-65-3, Formula: C16H16N6, MWT: 292.3384, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Cell Cycle/DNA Damage, Target: Haspin Kinase, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| VX-11e, Alternative-names: , CAS# 896720-20-0, Formula: C24H20Cl2FN5O2, MWT: 500.3523, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt;MAPK/ERK Pathway, Target: ERK;ERK, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| WAY 316606, Alternative-names: , CAS# 915759-45-4, Formula: C18H19F3N2O4S2, MWT: 448.4797, Solubility: 10 mM in DMSO, Clinical_Information: No Development Reported, Pathway: Stem Cell/Wnt, Target: sFRP-1, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
| Rofecoxib, Alternative-names: MK 966, CAS# 162011-90-7, Formula: C17H14O4S, MWT: 314.3557, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Immunology/Inflammation, Target: COX, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 100mg |
| Posaconazole, Alternative-names: SCH 56592, CAS# 171228-49-2, Formula: C37H42F2N8O4, MWT: 700.7774, Solubility: 10 mM in DMSO, Clinical_Information: Launched, Pathway: Anti-infection, Target: Fungal, HPLC>98%, NMR, LCMS, MSDS, COA is ok, stock more than 5mg |
